Pfizer (PFE) 10-Q 9 Nov 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Oct. 01, 2017	Nov. 06, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	PFIZER INC
Entity Central Index Key	78,003
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Oct. 1, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Amendment Flag	false
Trading Symbol	PFE
Entity Common Stock, Shares Outstanding		5,960,707,317

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016
Income Statement [Abstract]
Revenues	[1]	$ 13,168	$ 13,045	$ 38,843		$ 39,196
Costs and expenses:
Cost of sales	[1],[2]	2,847	3,085	7,980		9,111
Selling, informational and administrative expenses	[1],[2]	3,500	3,559	10,233		10,414
Research and development expenses	[1],[2]	1,859	1,881	5,346		5,360
Amortization of intangible assets	[1]	1,177	968	3,571		2,934
Restructuring charges and certain acquisition-related costs	[1]	149	531	377		988
Other (income)/deductions––net	[1]	51	1,417	(16)		2,815
Income from continuing operations before provision for taxes on income	[1],[3]	3,585	1,604	11,351		7,575
Provision for taxes on income	[1],[4]	727	249	2,287		1,109
Income from continuing operations	[1],[4],[5]	2,858	1,355	9,064		6,465
Discontinued operations––net of tax	[1]	0	0	1		0
Net income before allocation to noncontrolling interests	[1],[4],[6],[7]	2,858	1,355	9,066	[8]	6,465	[8]
Less: Net income attributable to noncontrolling interests	[1]	18	0	32		25
Net income attributable to Pfizer Inc.	[1],[4]	$ 2,840	$ 1,355	$ 9,034		$ 6,440
Earnings per common share––basic:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[4]	$ 0.48	$ 0.22	$ 1.51		$ 1.06
Discontinued operations––net of tax (in dollars per share)	[1],[4]	0	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[4]	0.48	0.22	1.51		1.06
Earnings per common share––diluted:
Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[4]	0.47	0.22	1.49		1.04
Discontinued operations––net of tax (in dollars per share)	[1],[4]	0	0	0		0
Net income attributable to Pfizer Inc. common shareholders (in dollars per share)	[1],[4]	$ 0.47	$ 0.22	$ 1.49		$ 1.04
Weighted-average shares––basic	[1]	5,951	6,066	5,972		6,095
Weighted-average shares––diluted	[1],[4],[5]	6,041	6,150	6,057		6,175
Cash dividends paid per common share (in dollars per share)	[1]	$ 0.32	$ 0.30	$ 0.96		$ 0.90
[1]	Amounts may not add due to rounding.
[2]	Excludes amortization of intangible assets, except as disclosed in Note 9A. Identifiable Intangible Assets and Goodwill: Identifiable Intangible Assets.
[3]	Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million , respectively, from our investment in ViiV. For additional information, see
[4]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards
[5]	Amounts for the third quarter and first nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016 , as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B
[6]	Amounts may not add due to rounding.
[7]	Amounts may not add due to rounding.
[8]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies

CONDENSED CONSOLIDATED STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016
Statement of Comprehensive Income [Abstract]
Net income before allocation to noncontrolling interests	[1],[2],[3],[4]	$ 2,858	$ 1,355	$ 9,066	[5]	$ 6,465	[5]
Foreign currency translation adjustments, net	[3]	878	417	1,352		998
Reclassification adjustments	[3],[6]	(3)	0	110		0
Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax	[3]	875	417	1,461		998
Unrealized holding losses on derivative financial instruments, net	[3]	(50)	(126)	(149)		(970)
Reclassification adjustments for realized (gains)/losses	[3],[7]	56	150	(393)		280
Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total	[3]	6	24	(542)		(690)
Unrealized holding gains on available-for-sale securities, net	[3]	384	261	698		740
Reclassification adjustments for realized gains	[3],[7]	(278)	(112)	(181)		(129)
Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total	[3]	106	149	518		611
Benefit plans: actuarial losses, net	[3]	(103)	(82)	(41)		(101)
Reclassification adjustments related to amortization	[3],[8]	140	140	448		418
Reclassification adjustments related to settlements, net	[3],[8]	38	28	89		76
Other	[3]	(76)	69	(111)		51
Defined benefit plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total	[3]	(1)	155	384		444
Benefit plans: prior service (costs)/credits and other, net	[3]	0	95	(2)		182
Reclassification adjustments related to amortization	[3],[8]	(46)	(45)	(138)		(127)
Reclassification adjustments related to curtailments, net	[3],[8]	(3)	(8)	(14)		(14)
Other	[3]	1	6	2		12
Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax	[3]	(48)	48	(151)		54
Other comprehensive income, before tax	[3]	938	793	1,669		1,417
Tax provision/(benefit) on other comprehensive income	[3],[9]	(80)	116	(218)		111
Other comprehensive income before allocation to noncontrolling interests	[3]	1,018	677	1,888		1,306
Comprehensive income before allocation to noncontrolling interests	[3]	3,876	2,031	10,953		7,771
Less: Comprehensive income attributable to noncontrolling interests	[3]	19	0	48		24
Comprehensive income attributable to Pfizer Inc.	[3]	$ 3,857	$ 2,032	$ 10,906		$ 7,747
[1]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards
[2]	Amounts may not add due to rounding.
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies
[6]	The foreign currency translation adjustments reclassified into Other (income)/deductions—net in the condensed consolidated statements of income primarily result from sale of our 40% ownership investment in Teuto. See Note 2D. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments
[7]	Reclassified into Other (income)/deductions—net and Cost of sales in the condensed consolidated statements of income. For additional information on amounts reclassified into Cost of sales, see
[8]	Generally reclassified, as part of net periodic pension cost, into Cost of sales, Selling, informational and administrative expenses, and/or Research and development expenses , as appropriate, in the condensed consolidated statements of income. For additional information, see Note 10. Pension and Postretirement Benefit Plans
[9]	See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.

CONDENSED CONSOLIDATED STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (PARENTHETICAL)	Jun. 30, 2017	Oct. 02, 2016
Laboratorio Teuto Brasilero [Member]
Equity method investment, ownership percentage	40.00%	40.00%

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Assets
Cash and cash equivalents	[1],[2]	$ 2,779	$ 2,595
Short-term investments	[2]	14,146	15,255
Trade accounts receivable, less allowance for doubtful accounts: 2017—$590; 2016—$609	[2]	10,002	8,225
Inventories	[2],[3]	7,925	6,783
Current tax assets	[2]	3,263	3,041
Other current assets	[2]	2,158	2,249
Assets held for sale	[2]	16	801
Total current assets	[2]	40,291	38,949
Long-term investments	[2]	7,311	7,116
Property, plant and equipment, less accumulated depreciation: 2017—$15,906; 2016—$14,807	[2]	13,505	13,318
Identifiable intangible assets, less accumulated amortization	[2],[4]	49,721	52,648
Goodwill	[2]	56,078	54,449
Noncurrent deferred tax assets and other noncurrent tax assets	[2]	1,858	1,812
Other noncurrent assets	[2]	3,388	3,323
Total assets	[2]	172,151	171,615
Liabilities and Equity
Short-term borrowings, including current portion of long-term debt: 2017—$3,072; 2016—$4,225	[2],[5]	9,448	10,688
Trade accounts payable	[2]	3,480	4,536
Dividends payable	[2]	1,909	1,944
Income taxes payable	[2]	1,003	437
Accrued compensation and related items	[2]	1,932	2,487
Other current liabilities	[2]	10,446	11,023
Total current liabilities	[2]	28,217	31,115
Long-term debt	[2],[6]	34,503	31,398
Pension benefit obligations, net	[2]	5,531	6,406
Postretirement benefit obligations, net	[2]	1,687	1,766
Noncurrent deferred tax liabilities	[2]	30,411	30,753
Other taxes payable	[2]	4,304	4,000
Other noncurrent liabilities	[2]	6,388	6,337
Total liabilities	[2]	111,041	111,776
Commitments and Contingencies	[2]
Preferred stock	[2]	22	24
Common stock	[2]	463	461
Additional paid-in capital	[2]	83,827	82,685
Treasury stock	[2]	(89,421)	(84,364)
Retained earnings	[2]	75,043	71,774
Accumulated other comprehensive loss	[2]	(9,164)	(11,036)
Total Pfizer Inc. shareholders’ equity	[2]	60,770	59,544
Equity attributable to noncontrolling interests	[2]	340	296
Total equity	[2]	61,110	59,840
Total liabilities and equity	[2]	$ 172,151	$ 171,615
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.
[3]	The change from December 31, 2016
[4]	The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A ), as well as impairments of Developed technology rights (see Note 4) , partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E
[5]	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 1, 2017 or December 31, 2016 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our priv
[6]	The fair value of our long-term debt (not including the current portion of long-term debt) was $39.0 billion as of October 1, 2017 and $34.9 billion as of December 31, 2016 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of $4.7 billion as of October 1, 2017

CONDENSED CONSOLIDATED BALANCE6

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	[1]	$ 590	$ 609
Property, plant and equipment, accumulated depreciation	[1]	15,906	14,807
Current portion of long-term debt	[1]	$ 3,072	$ 4,225
[1]	Amounts may not add due to rounding.

CONDENSED CONSOLIDATED STATEME7

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions		9 Months Ended
		Oct. 01, 2017		Oct. 02, 2016
Operating Activities
Net income before allocation to noncontrolling interests	[1],[2],[3],[4],[5]	$ 9,066		$ 6,465
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:
Depreciation and amortization	[5]	4,695		4,208
Asset write-offs and impairments	[5]	326		1,146
Loss on sale of HIS net assets	[5],[6]	52		1,422
Deferred taxes from continuing operations	[5]	241		(1,335)
Share-based compensation expense	[5]	595		532
Benefit plan contributions in excess of expense	[5]	(1,042)		(775)
Other adjustments, net	[5]	(561)		68
Other changes in assets and liabilities, net of acquisitions and divestitures	[1],[5]	(3,644)		(1,582)
Net cash provided by operating activities	[1],[5]	9,728		10,151
Investing Activities
Purchases of property, plant and equipment	[5]	(1,256)		(1,134)
Purchases of short-term investments	[5]	(6,469)		(15,170)
Proceeds from redemptions/sales of short-term investments	[5]	5,783		20,685
Net proceeds from redemptions/sales of short-term investments with original maturities of three months or less	[5]	2,758		6,485
Purchases of long-term investments	[5]	(2,526)		(4,771)
Proceeds from redemptions/sales of long-term investments	[5]	2,417		6,915
Acquisitions of businesses, net of cash acquired	[5]	(1,000)		(17,679)
Acquisitions of intangible assets	[5]	(188)		(96)
Other investing activities, net	[5]	519		60
Net cash provided by/(used in) investing activities	[5]	38		(4,704)
Financing Activities
Proceeds from short-term borrowings	[5]	7,003		6,397
Principal payments on short-term borrowings	[5]	(7,691)		(3,321)
Net proceeds from/(payments on) short-term borrowings with original maturities of three months or less	[5]	555		(963)
Proceeds from issuance of long-term debt	[5]	5,273		5,031
Principal payments on long-term debt	[5]	(4,474)		(4,317)
Purchases of common stock	[5]	(5,000)		(5,000)
Cash dividends paid	[5]	(5,750)		(5,496)
Proceeds from exercise of stock options	[5]	656		946
Other financing activities, net	[1],[5]	(223)		(192)
Net cash used in financing activities	[1],[5]	(9,650)		(6,915)
Effect of exchange-rate changes on cash and cash equivalents	[5]	67		(79)
Net increase/(decrease) in cash and cash equivalents	[5]	184		(1,547)
Cash and cash equivalents, beginning	[5]	2,595	[7]	3,641
Cash and cash equivalents, end	[5]	2,779	[7]	2,094
Non-cash transactions:
Receipt of ICU Medical common stock	[5],[8]	428		0
Promissory note from ICU Medical	[5],[8]	75		0
Cash paid (received) during the period for:
Income taxes	[5]	1,424		1,430
Interest	[5]	1,101		1,177
Interest rate hedges	[5]	$ (183)		$ (356)
[1]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies
[2]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards
[3]	Amounts may not add due to rounding.
[4]	Amounts may not add due to rounding.
[5]	Amounts may not add due to rounding.
[6]	In the third quarter and first nine months of 2017 , represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.
[7]	Amounts may not add due to rounding.
[8]	In connection with the sale of HIS net assets to ICU Medical, on February 3, 2017, Pfizer received 3.2 million newly issued shares of ICU Medical common stock initially valued at $428 million and a promissory note in the amount of $75 million . For additional information, see Note 2B . Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments

CONDENSED CONSOLIDATED STATEME8

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (PARENTHETICAL) - HIS [Member] - Disposed of by Sale [Member] - ICU Medical [Member] shares in Millions, $ in Millions	Feb. 03, 2017USD ($)shares
Number of shares received in disposition | shares	3.2
Value of shares received from disposition	$ 428
Promissory note	$ 75

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Oct. 01, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	Basis of Presentation and Significant Accounting Policies A. Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 27, 2017 and August 28, 2016 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 1, 2017 and October 2, 2016 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2016 Form 10-K. We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). For additional information, see Note 13 and Notes to Consolidated Financial Statements–– Note 18. Segment, Geographic and Other Revenue Information in Pfizer’s 2016 Financial Report. Certain amounts in the condensed consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts. Our recent significant business development activities include: • On February 3, 2017, we completed the sale of our global infusion therapy net assets, HIS, to ICU Medical. The operating results of HIS are included in our condensed consolidated statement of income and EH’s operating results through February 2, 2017 and, therefore, our financial results, and EH’s operating results, for the third quarter of 2017 do not reflect any contribution from HIS global operations, while our financial results, and EH’s operating results, for the third quarter of 2016 reflect three months of HIS global operations. Our financial results, and EH’s operating results, for the first nine months of 2017 reflect approximately one month of HIS domestic operations and approximately two months of HIS international operations, while our financial results, and EH’s operating results, for the first nine months of 2016 reflect nine months of HIS global operations. Assets and liabilities associated with HIS are presented as held for sale in the condensed consolidated balance sheet as of December 31, 2016. The HIS assets held for sale are reported in Assets held for sale and HIS liabilities held for sale are reported in Other current liabilities. • On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of this business, and, in accordance with our international reporting period, our financial results, EH’s operating results, and cash flows for the third quarter and first nine months of 2017 reflect approximately three months and eight months, respectively, of the small molecule anti-infectives business acquired from AstraZeneca. • On September 28, 2016, we acquired Medivation for $81.50 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Medivation. Therefore, Medivation operations are reflected in our financial results, IH’s operating results, and cash flows for the third quarter and first nine months of 2017 . In accordance with our domestic and international reporting periods, our consolidated financial statements for the third quarter and first nine months of 2016 reflect three business days of Medivation operations, which were immaterial. • On June 24, 2016, we acquired Anacor for $99.25 per share. Commencing from the acquisition date, our financial statements reflect the assets, liabilities, operating results and cash flows of Anacor. Therefore, Anacor operations are reflected in our financial results, IH’s operating results, and cash flows for the third quarter and first nine months of 2017 . In accordance with our domestic and international reporting periods, our consolidated financial statements for the third quarter and first nine months of 2016 reflect approximately three months of Anacor operations. For additional information, see Note 2 and Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments in Pfizer’s 2016 Financial Report. B. Adoption of New Accounting Standards In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the Provision for taxes on income , whereas excess tax benefits or deficiencies previously were recognized in Additional paid-in capital . The net tax benefit for the Company was $35 million for the third quarter of 2016 and $85 million for the first nine months of 2016 . Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, $87 million of cash outflows for the first nine months of 2016 was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards included in our 2016 Financial Report. We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.

Acquisitions, Sale of Hospira I

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments	9 Months Ended
	Oct. 01, 2017
Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]
Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments	Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments A. Acquisitions AstraZeneca’s Small Molecule Anti-Infectives Business (EH) On December 22, 2016, which falls in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca’s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the newly approved EU drug Zavicefta™ (ceftazidime-avibactam), the marketed agents Merrem™/Meronem™ (meropenem) and Zinforo™ (ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). Under the terms of the agreement, we made an upfront payment of approximately $552 million to AstraZeneca upon the close of the transaction and an additional $3 million payment for a contractual purchase price adjustment in the second quarter of 2017. We also made a $50 million milestone payment in the second quarter of 2017, we expect to make an additional milestone payment of $125 million in our first fiscal quarter of 2018 and we will make a deferred payment of $175 million to AstraZeneca in January 2019. In addition, AstraZeneca may be eligible to receive an additional milestone payment of $75 million if the related milestone is achieved prior to December 31, 2021, and up to $600 million if sales of Zavicefta™ exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta™ and ATM-AVI in certain markets for a period ending on the later of ten years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately $250 million to $425 million . The total fair value of consideration transferred for AstraZeneca’s small molecule anti-infectives business was approximately $1,045 million , which includes $555 million in cash, plus the fair value of contingent consideration of $490 million (which is composed of the deferred payment, the $50 million milestone payment made in the second quarter of 2017 and the future expected milestone and royalty payments). In connection with this acquisition, we provisionally recorded $879 million in Identifiable intangible assets , primarily consisting of $660 million in Developed technology rights and $219 million in IPR&D . We also recorded $92 million in Other current assets related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, $92 million in Goodwill and $17 million of net deferred tax liabilities. The allocation of the consideration transferred to the assets and the liabilities assumed has not yet been finalized. Medivation, Inc. (IH) On September 28, 2016, we acquired Medivation for $81.50 per share. The total fair value of consideration transferred for Medivation was approximately $14.3 billion in cash ( $13.9 billion , net of cash acquired). Of this consideration, approximately $365 million was not paid as of December 31, 2016, and was recorded in Other current liabilities. Substantially all of the remaining consideration was paid as of October 1, 2017 . Medivation is now a wholly-owned subsidiary of Pfizer. Medivation is a biopharmaceutical company focused on developing and commercializing small molecules for oncology. Medivation’s portfolio includes Xtandi (enzalutamide), an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. In addition, Medivation has a development-stage oncology asset in its pipeline, talazoparib, which is currently in a Phase 3 study for the treatment of BRCA-mutated breast cancer. In connection with this acquisition, we recorded $12.2 billion in Identifiable intangible assets , primarily consisting of $8.1 billion of Developed technology rights with an average useful life of approximately 12 years and $4.1 billion of IPR&D, and recorded $6.1 billion of Goodwill, $4.0 billion of net income tax liabilities, and $259 million of assumed contingent consideration. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in Identifiable intangible assets of approximately $1.0 billion with a corresponding change to Goodwill and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The third quarter and first nine months of 2017 results include a decrease of approximately $38 million to Amortization of intangible assets which reflects the cumulative pre-tax impact of the measurement period adjustments to Identifiable intangible assets that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. Bamboo Therapeutics, Inc. (IH) On August 1, 2016, we acquired all the remaining equity in Bamboo, a privately-held biotechnology company focused on developing gene therapies for the potential treatment of patients with certain rare diseases relating to neuromuscular conditions and those affecting the central nervous system, for $150 million , plus potential milestone payments of up to $495 million contingent upon the progression of key assets through development, regulatory approval and commercialization. The total fair value of the consideration transferred for Bamboo was approximately $343 million , including cash of $130 million ( $101 million , net of cash acquired), contingent consideration of $167 million , consisting of milestone payments, and the fair value of Pfizer’s previously held equity interest in Bamboo of $45 million . We previously purchased a minority stake in Bamboo in the first quarter of 2016 for a payment of approximately $43 million . Upon acquiring the remaining interest in Bamboo in the third quarter of 2016 , we recognized a gain of $2 million on our existing investment in Other (income)/deductions––net over the one- year allocation period . This acquisition provides us with several clinical and pre-clinical assets that complement our rare disease portfolio, an advanced recombinant AAV vector design and production technology, and a fully functional Phase I/II gene therapy manufacturing facility. Bamboo is now a wholly-owned subsidiary of Pfizer. In connection with this acquisition, we recorded $330 million of Identifiable intangible assets, consisting entirely of IPR&D. We also recorded $142 million of Goodwill and $94 million of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. Anacor Pharmaceuticals, Inc. (IH) On June 24, 2016, we acquired Anacor for $99.25 per share. The total fair value of consideration transferred for Anacor was approximately $4.9 billion in cash ( $4.5 billion net of cash acquired), plus $698 million debt assumed. Anacor is now a wholly-owned subsidiary of Pfizer. Anacor is a biopharmaceutical company focused on novel small-molecule therapeutics derived from its boron chemistry platform. Anacor’s crisaborole, a non-steroidal topical PDE-4 inhibitor with anti-inflammatory properties, was approved by the FDA on December 14, 2016 under the trade name, Eucrisa. In connection with this acquisition, we recorded $698 million as the fair value of notes payable in cash, and recorded $4.9 billion in Identifiable intangible assets , primarily consisting of $4.8 billion of IPR&D , and recorded $646 million of Goodwill and $346 million of net income tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed. B. Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical would acquire all of our global infusion therapy net assets, HIS, for approximately $1 billion in cash and ICU Medical common stock . HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU Medical’s expectations, on January 5, 2017, we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately $900 million , composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. The revised transaction closed on February 3, 2017. At closing, under the terms of the revised agreement, we received 3.2 million newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately $428 million (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which are reported as available-for-sale equity securities at fair value in Long-term investments on the condensed consolidated balance sheet as of October 1, 2017 , a promissory note in the amount of $75 million , which is reported in Other noncurrent assets on the condensed consolidated balance sheet as of October 1, 2017 , and net cash of approximately $200 million before customary adjustments for net working capital, which is reported in Other investing activities, net on the condensed consolidated statement of cash flows for the nine months ended October 1, 2017 . In addition, we are entitled to receive a contingent amount of up to an additional $225 million in cash based on ICU Medical’s achievement of certain cumulative performance targets for the combined company through December 31, 2019. After receipt of the ICU Medical shares, we own approximately 16% of ICU Medical. We have agreed to certain restrictions on transfer of our ICU Medical shares for 18 months after the closing date. The promissory note from ICU Medical has a term of three years and bears interest at LIBOR plus 2.25% for the first year and LIBOR plus 2.50% for the second and third years. We recognized pre-tax income of approximately $12 million in the third quarter of 2017 and pre-tax losses of approximately $52 million in the first nine months of 2017 in Other (income)/deductions––net, representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell. For additional information, see Note 4 and Notes to Consolidated Financial Statements–– Note 2. Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments in Pfizer’s 2016 Financial Report. While we have received the full purchase price excluding the contingent amount as of the February 3, 2017 closing, the sale of the HIS net assets was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, which represent a relatively small portion of the HIS net assets, we have continued to operate the net assets for the net economic benefit of ICU Medical, and we are indemnified by ICU Medical against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. Sales of the HIS net assets have occurred in certain of these jurisdictions as of October 1, 2017 and we expect the sale of the HIS net assets in the remaining jurisdictions to be fully completed by the first quarter of 2018. As such, and as we have already received all of the non-contingent proceeds from the sale and ICU Medical is contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes. In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale. C. Collaboration Arrangement Collaboration with Merck & Co., Inc. In 2013, we entered into a worldwide, except for Japan, collaboration agreement with Merck for the development and commercialization of ertugliflozin (PF-04971729), our oral sodium glucose cotransporter (SGLT2) inhibitor for the treatment of type 2 diabetes currently under regulatory review. Under the agreement, we are collaborating with Merck on the clinical development of ertugliflozin, and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets. In the first quarter of 2017 , we received a $90 million milestone payment from Merck upon the FDA’s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which has been deferred and primarily reported in Other noncurrent liabilities and is being recognized in Other (income)/deductions––net over a multi-year period. We are eligible for additional payments associated with the achievement of future clinical, regulatory and commercial milestones. We share potential revenues and certain costs with Merck on a 60% / 40% basis, with Pfizer having the 40% share. D. Equity-Method Investments Investment in Hisun Pfizer Pharmaceuticals Company Limited In 2016 , we determined that we had other-than-temporary declines in the value of Hisun Pfizer, our 49% -owned equity-method investment in China, and, therefore, we recognized a loss of $211 million for the first nine months of 2016 in Other (income)/deductions––net (see Note 4 ) . The declines in value resulted from lower expectations as to the future cash flows to be generated by Hisun Pfizer, primarily as a result of an increase in risk due to the continued slowdown in the Chinese economy and changes in the expected timing and number of new product introductions by Hisun Pfizer. As of October 1, 2017 , the carrying value of our investment in Hisun Pfizer is $270 million , which is included in Long-term investments . We are continuing to evaluate strategic alternatives with Hisun. These strategic alternatives could impact the value of our investment in Hisun Pfizer in future periods. In valuing our investment in Hisun Pfizer, we used discounted cash flow techniques, reflecting our best estimate of the various risks inherent in the projected cash flows, and a nominal terminal year growth factor. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal, economic and/or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long-term; and the discount rate, which seeks to reflect the various risks inherent in the projected cash flows, including country risk. Investment in Laboratório Teuto Brasileiro S.A. We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a 40% -owned generics company in Brazil, and sell our 40% interest in Teuto to the majority shareholders. As part of the agreement, we have waived our option to acquire the remaining 60% of Teuto, and Teuto’s other shareholders have waived their option to sell their 60% stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately $30 million in Other (income)/deductions––net (see Note 4 ), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders’ option to sell their 60% stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017. In 2016 , we determined that we had an other-than-temporary decline in the value of Teuto, and, therefore, we recognized a loss of $50 million for the first nine months of 2016 in Other (income)/deductions––net (see Note 4 ) related to our equity-method investment. The decline in value resulted from lower expectations as to the future cash flows to be generated by Teuto, primarily due to a slowdown in Brazilian economic conditions, which have been impacted by political risk, higher inflation, and the depreciation of the Brazilian real.

Restructuring Charges and Other

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	9 Months Ended
	Oct. 01, 2017
Restructuring and Related Activities [Abstract]
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example: • In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and • In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems. All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&D, as well as groups such as information technology, shared services and corporate operations. In connection with our acquisition of Hospira, we are focusing our efforts on achieving an appropriate cost structure for the combined company. For up to a three-year period post-acquisition, we expect to incur costs of approximately $1 billion (not including costs of $215 million for full-year 2015 associated with the return of acquired IPR&D rights as described in the Current-Period Key Activities section of Notes to Consolidated Financial Statements–– Note 3 . Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives in our 2016 Financial Report) associated with the integration of Hospira. In 2016, we substantially completed previously disclosed cost-reduction initiatives begun in 2014 associated with our global commercial structure reorganization, manufacturing plant network rationalization and optimization initiatives, and additional cost-reduction/productivity initiatives across the enterprise. As a result of the evaluation performed in connection with our decision in September 2016 to not pursue, at that time, splitting IH and EH into two separate publicly-traded companies, we identified new opportunities to potentially achieve greater optimization and efficiency to become more competitive in our business. Therefore, in early 2017 , we initiated new enterprise-wide cost reduction/productivity initiatives, which we expect to substantially complete by the end of 2019. These initiatives will encompass all areas of our cost base and will include: • Optimization of our manufacturing plant network to support IH and EH products and pipelines. During 2017-2019, we expect to incur costs of approximately $800 million related to this initiative. Through October 1, 2017 , we incurred approximately $122 million associated with this initiative. • Activities in non-manufacturing related areas, which include further centralization of our corporate and platform functions, as well as other activities where opportunities are identified. During 2017-2019, we expect to incur costs of approximately $200 million related to this initiative. Through October 1, 2017 , we incurred approximately $131 million associated with this initiative. The costs expected to be incurred during 2017-2019, of approximately $1.0 billion for the above-mentioned programs (but not including expected costs associated with the Hospira integration), include restructuring charges, implementation costs and additional depreciation––asset restructuring. Of this amount, we expect that about 20% of the total charges will be non-cash. Current-Period Key Activities For the first nine months of 2017 , we incurred costs of $253 million associated with the 2017-2019 program, $238 million associated with the integration of Hospira and $110 million associated with all other acquisition-related initiatives. The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Restructuring charges (a) : Employee terminations $ (20 ) $ 347 $ 9 $ 464 Asset impairments (b) 101 27 126 45 Exit costs 10 29 16 64 Total restructuring charges 91 404 150 574 Transaction costs (c) (14 ) 54 4 114 Integration costs (d) 73 74 224 300 Restructuring charges and certain acquisition-related costs 149 531 377 988 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 39 46 74 145 Research and development expenses — 1 — 5 Total additional depreciation––asset restructuring 39 47 74 151 Implementation costs recorded in our condensed consolidated statements of income as follows (f) : Cost of sales 26 46 77 127 Selling, informational and administrative expenses 22 23 46 56 Research and development expenses 9 8 26 17 Other (income)/deductions––net — 1 — 2 Total implementation costs 57 78 150 202 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 245 $ 655 $ 601 $ 1,341 (a) In the third quarter and first nine months of 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the third quarter and first nine months of 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first nine months ended October 1, 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities for 2017 are associated with the following: • For the third quarter of 2017 , IH ( $4 million ); EH ( $1 million ); WRD/GPD ( $15 million ); manufacturing operations ( $47 million ); and Corporate ( $25 million ). • For the first nine months of 2017 , IH ( $10 million ); EH ( $9 million income); WRD/GPD ( $29 million ); manufacturing operations ( $70 million ); and Corporate ( $51 million ). The restructuring activities for 2016 are associated with the following: • For the third quarter of 2016 , IH ( $148 million ); EH ( $28 million ); WRD/GPD ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million ). (b) The asset impairment charges for the third quarter and the first nine months of 2017 are largely associated with our acquisitions of Hospira and Medivation. (c) Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the third quarter of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the first nine months of 2017 are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the third quarter of 2016 were mostly related to the Medivation acquisition, and in the first nine months of 2016 , were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan. (d) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter and first nine months of 2017 , integration costs primarily relate to our acquisitions of Hospira and Medivation. The first nine months of 2017 also include a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10 ). In the third quarter of 2016 , integration costs were mostly related to our acquisition of Hospira, and in the first nine months of 2016 , integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan. (e) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (f) Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives. The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2016 (a) $ 1,547 $ — $ 36 $ 1,583 Provision 9 126 16 150 Utilization and other (b) (401 ) (126 ) (24 ) (551 ) Balance, October 1, 2017 (c) $ 1,154 $ — $ 28 $ 1,182 (a) Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $533 million ) and Other noncurrent liabilities ( $650 million

Other (Income)_Deductions - Net

Other (Income)/Deductions - Net	9 Months Ended
	Oct. 01, 2017
Other Income and Expenses [Abstract]
Other (Income)/Deductions - Net	Other (Income)/Deductions—Net The following table provides components of Other (income)/deductions––net : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Interest income (a) $ (99 ) $ (123 ) $ (275 ) $ (357 ) Interest expense (a) 320 291 940 889 Net interest expense 220 168 666 532 Royalty-related income (b) (140 ) (233 ) (331 ) (695 ) Certain legal matters, net (c) 183 (40 ) 194 494 Net gains on asset disposals (d) (155 ) (47 ) (349 ) (81 ) Loss on sale and impairment on remeasurement of HIS net assets (e) (12 ) 1,422 52 1,422 Certain asset impairments (f) 130 133 143 1,080 Business and legal entity alignment costs (g) 16 69 54 180 Other, net (h) (191 ) (55 ) (445 ) (117 ) Other (income)/deductions––net $ 51 $ 1,417 $ (16 ) $ 2,815 (a) Interest income decreased in the third quarter and first nine months of 2017 , primarily driven by a lower investment balance. Interest expense increased in the third quarter and first nine months of 2017 , primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt . (b) Royalty-related income decreased in the third quarter and first nine months of 2017 , primarily due to lower royalty income for Enbrel of $139 million and $414 million , respectively, resulting from the expiration on October 31, 2016 of the 36 -month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $73 million and $160 million , respectively. (c) In the third quarter and first nine months of 2017 , primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a $79 million charge to reflect damages awarded by a jury in a patent matter. In the first nine months of 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the first nine months of 2016 includes a settlement related to a patent matter. (d) In the third quarter of 2017 , primarily includes gains on sales/out-licensing of product and compound rights (approximately $71 million ) and gains on sales and redemptions of investments in equity and debt securities (approximately $66 million ). In the first nine months of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $183 million ), gains on sales/out-licensing of product and compound rights (approximately $141 million ) and a gain on sale of property (approximately $52 million ), partially offset by a net loss related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest (approximately $30 million ). In the first nine months of 2016 , includes gains on sales/out-licensing of product and compound rights (approximately $49 million ). (e) In the third quarter and first nine months of 2017 , represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. (f) In the third quarter and first nine months of 2017 , primarily includes an intangible asset impairment charge of $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the third quarter and first nine months of 2017 is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the third quarter of 2016 , primarily includes intangible asset impairment charges of $126 million , reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ( $97 million ) and IH ( $29 million ). In the first nine months of 2016 , primarily includes intangible asset impairment charges of $767 million , reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ( $738 million ) and IH ( $29 million ). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer’s 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. (g) In the third quarter and first nine months of 2017 and 2016 , represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (h) In the third quarter and first nine months of 2017 , includes, among other things, dividend income of $54 million and $211 million , respectively, from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In the first nine months of 2016 , includes, among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction and income of $116 million from resolution of a contract disagreement. The following table provides additional information about the intangible assets that were impaired during 2017 in Other (income)/deductions––net : Fair Value (a) Nine Months Ended October 1, 2017 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– Developed technology rights (b) $ 50 $ — $ — $ 50 $ 127 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the third quarter of 2017

Tax Matters

Tax Matters	9 Months Ended
	Oct. 01, 2017
Income Tax Disclosure [Abstract]
Tax Matters	Tax Matters A. Taxes on Income from Continuing Operations Our effective tax rate for continuing operations was 20.3% for the third quarter of 2017 , compared to 15.5% for the third quarter of 2016 and was 20.1% for the first nine months of 2017 , compared to 14.6% for the first nine months of 2016 . The higher effective tax rate for the third quarter of 2017 in comparison with the same period in 2016 was primarily due to: • an unfavorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, partially offset by: • the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets. The higher effective tax rate for the first nine months of 2017 in comparison with the same period in 2016 was primarily due to: • the non-recurrence of benefits related to the final resolution of an agreement in principle reached in February 2016 and finalized in April 2016 to resolve certain claims related to Protonix, which resulted in the receipt of information that raised our initial assessment in 2015 of the likelihood of prevailing on the technical merits of our tax position; • the non-recurrence of benefits associated with our Venezuela operations; as well as • a decrease in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations, partially offset by: • the change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as • the non-recurrence of the unfavorable tax effects of an impairment charge related to the write-down of HIS net assets to fair value less estimated costs to sell, mainly related to goodwill, which is not deductible for tax purposes, and the jurisdictional mix of intangible assets. B. Tax Contingencies We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS: • With respect to Pfizer, the IRS has issued a Revenue Agent’s Report (RAR) for tax years 2009-2010. We are not in agreement with the RAR and are currently appealing certain disputed issues. Tax years 2011-2013 are currently under audit. Tax years 2014-2017 are open, but not under audit. All other tax years are closed. • With respect to Hospira, the federal income tax audit for tax years 2012-2013 was effectively settled in the third quarter of 2017. The IRS is currently auditing tax year 2014 through short-year 2015. All other tax years are closed. The tax years under audit for Hospira are not considered material to Pfizer. • With respect to Anacor and Medivation, the open tax years are not considered material to Pfizer. In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2010-2017), Japan (2015-2017), Europe (2011-2017, primarily reflecting Ireland, the United Kingdom, France, Italy, Spain and Germany), Latin America (1998-2017, primarily reflecting Brazil) and Puerto Rico (2010-2017). C. Tax Provision/(Benefit) on Other Comprehensive Income The following table provides the components of Tax provision/(benefit) on other comprehensive income: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Foreign currency translation adjustments, net (a) $ (62 ) $ — $ (192 ) $ (15 ) Unrealized holding losses on derivative financial instruments, net 28 — 30 (192 ) Reclassification adjustments for realized (gains)/losses (29 ) 32 (169 ) 81 (1 ) 32 (139 ) (112 ) Unrealized holding gains on available-for-sale securities, net 37 40 93 106 Reclassification adjustments for realized gains (49 ) (14 ) (45 ) (16 ) (12 ) 26 47 90 Benefit plans: actuarial losses, net (37 ) (31 ) (15 ) (39 ) Reclassification adjustments related to amortization 60 47 152 140 Reclassification adjustments related to settlements, net 22 10 30 27 Other (33 ) 14 (46 ) 5 11 40 121 133 Benefit plans: prior service (costs)/credits and other, net — 35 — 66 Reclassification adjustments related to amortization (17 ) (17 ) (50 ) (47 ) Reclassification adjustments related to curtailments, net (1 ) (3 ) (5 ) (5 ) Other 1 2 1 1 (17 ) 18 (55 ) 15 Tax provision/(benefit) on other comprehensive income $ (80 ) $ 116 $ (218 ) $ 111 (a)

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	9 Months Ended
	Oct. 01, 2017
Equity [Abstract]
Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests	Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2016 $ (6,659 ) $ 348 $ (131 ) $ (5,473 ) $ 879 $ (11,036 ) Other comprehensive income/(loss) (a) 1,638 (403 ) 470 263 (96 ) 1,872 Balance, October 1, 2017 $ (5,021 ) $ (55 ) $ 339 $ (5,210 ) $ 783 $ (9,164 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $16 million income for the first nine months of 2017 . As of October 1, 2017 , with respect to derivative financial instruments, the amount of unrealized pre-tax net losses on derivative financial instruments estimated to be reclassified into income within the next 12 months is approximately $154 million

Financial Instruments

Financial Instruments	9 Months Ended
	Oct. 01, 2017
Financial Instruments [Abstract]
Financial Instruments	Financial Instruments A. Selected Financial Assets and Liabilities The following table provides additional information about certain of our financial assets and liabilities: (MILLIONS OF DOLLARS) October 1, December 31, Selected financial assets measured at fair value on a recurring basis (a) Trading funds and securities (b) $ 347 $ 325 Available-for-sale debt securities (c) 16,598 18,632 Money market funds 1,824 1,445 Available-for-sale equity securities (c) 1,032 540 Derivative financial instruments in a receivable position (d) : Interest rate swaps 630 625 Foreign currency swaps 92 79 Foreign currency forward-exchange contracts 110 551 20,631 22,198 Other selected financial assets Held-to-maturity debt securities, carried at amortized cost (c), (e) 1,464 1,242 Restricted stock and private equity securities, carried at cost or at equity-method (e) 719 735 2,183 1,977 Total selected financial assets $ 22,815 $ 24,175 Selected financial liabilities measured at fair value on a recurring basis (a) Derivative financial instruments in a liability position (f) : Interest rate swaps $ 154 $ 148 Foreign currency swaps 710 1,374 Foreign currency forward-exchange contracts 309 143 1,173 1,665 Other selected financial liabilities Short-term borrowings: Principal amount 9,460 10,674 Net fair value adjustments related to hedging and purchase accounting 2 24 Net unamortized discounts, premiums and debt issuance costs (15 ) (11 ) Total short-term borrowings, carried at historical proceeds, as adjusted (e) 9,448 10,688 Long-term debt: Principal amount 33,671 30,529 Net fair value adjustments related to hedging and purchase accounting 981 998 Net unamortized discounts, premiums and debt issuance costs (149 ) (130 ) Total long-term debt, carried at historical proceeds, as adjusted (g) 34,503 31,398 43,951 42,085 Total selected financial liabilities $ 45,124 $ 43,750 (a) We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except 5% that use Level 1 inputs. (b) As of October 1, 2017 , trading funds and securities are composed of $274 million of trading equity funds and $74 million of trading debt funds. As of December 31, 2016 , trading funds and securities are composed of $236 million of trading equity funds and $89 million of trading debt funds. As of October 1, 2017 and December 31, 2016 , trading equity funds of $63 million and $71 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. (c) Gross unrealized gains and losses are not significant, except as of October 1, 2017 , available-for-sale equity securities’ unrealized gains are $406 million and unrealized losses are $119 million . (d) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $40 million as of October 1, 2017 ; and foreign currency forward-exchange contracts with fair values of $162 million as of December 31, 2016 . (e) The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 1, 2017 or December 31, 2016 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our priv ate equity securities carried at cost are based on Level 3 inputs. (f) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $60 million as of October 1, 2017 ; and foreign currency swaps with fair values of $269 million and foreign currency forward-exchange contracts with fair values of $113 million as of December 31, 2016 . (g) The fair value of our long-term debt (not including the current portion of long-term debt) was $39.0 billion as of October 1, 2017 and $34.9 billion as of December 31, 2016 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of $4.7 billion as of October 1, 2017 , which are used as hedging instruments. The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets: (MILLIONS OF DOLLARS) October 1, December 31, Assets Cash and cash equivalents $ 526 $ 547 Short-term investments 14,146 15,255 Other current assets (a) 288 567 Long-term investments 7,311 7,116 Other noncurrent assets (b) 543 689 $ 22,815 $ 24,175 Liabilities Short-term borrowings, including current portion of long-term debt $ 9,448 $ 10,688 Other current liabilities (c) 277 443 Long-term debt 34,503 31,398 Other noncurrent liabilities (d) 896 1,222 $ 45,124 $ 43,750 (a) As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $97 million ), foreign currency swaps ( $86 million ) and foreign currency forward-exchange contracts ( $105 million ) and, as of December 31, 2016 , include interest rate swaps ( $26 million ), foreign currency swaps ( $43 million ) and foreign currency forward-exchange contracts ( $497 million ). (b) As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $532 million ), foreign currency swaps ( $6 million ) and foreign currency forward-exchange contracts ( $5 million ) and, as of December 31, 2016 , include interest rate swaps ( $599 million ), foreign currency swaps ( $36 million ) and foreign currency forward-exchange contracts ( $54 million ). (c) As of October 1, 2017 , derivative instruments at fair value include foreign currency forward-exchange contracts ( $276 million ) and interest rate swaps ( $1 million ) and, as of December 31, 2016 , include interest rate swaps ( $1 million ), foreign currency swaps ( $300 million ) and foreign currency forward-exchange contracts ( $143 million ). (d) As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $153 million ), foreign currency swaps ( $710 million ) and foreign currency forward-exchange contracts ( $33 million ) and, as of December 31, 2016 , include interest rate swaps ( $147 million ) and foreign currency swaps ( $1.1 billion ). There were no significant impairments of financial assets recognized in any period presented. B. Investments in Debt Securities The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: Years October 1, (MILLIONS OF DOLLARS) Within 1 Over 1 to 5 Over 5 to 10 Over 10 Total Available-for-sale debt securities Corporate debt (a) $ 2,741 $ 2,591 $ 1,525 $ 17 $ 6,874 Western European, Asian, and other government debt (b) 6,071 268 — — 6,339 Western European, Scandinavian and other government agency debt (b) 1,955 42 — — 1,998 Supranational debt (b) 387 195 — — 582 Government National Mortgage Association and other U.S. government guaranteed asset-backed securities 42 424 — — 466 Other asset-backed debt (c) 161 61 3 — 226 U.S. government debt — 112 — — 112 Held-to-maturity debt securities Time deposits and other 1,133 — 3 — 1,137 Western European government debt (b) 326 — — — 326 Total debt securities $ 12,818 $ 3,694 $ 1,532 $ 18 $ 18,061 (a) Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade. (b) Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality. (c) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages. C. Short-Term Borrowings Short-term borrowings include amounts for commercial paper of $6.1 billion as of October 1, 2017 and $5.8 billion as of December 31, 2016 . D. Long-Term Debt The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017: Principal As of October 1, 2017 (MILLIONS) Maturity Date Euro U.S. Dollar 3-month EURIBOR + 0.20% floating rate notes (0% floor) March 6, 2019 € 1,250 $ 1,479 0.00% euro notes (a) March 6, 2020 1,000 1,183 0.25% euro notes (a) March 6, 2022 1,000 1,183 1.00% euro notes (a) March 6, 2027 750 887 Total euro long-term debt issued in the first quarter of 2017 (b) € 4,000 $ 4,732 4.20% notes (c) March 17, 2047 1,065 Total long-term debt issued in the first quarter of 2017 (d) $ 5,797 (a) Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus 0.15% ; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date. (b) The weighted-average effective interest rate for the euro notes at issuance was 0.23% . (c) The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020. (d) The aggregate amount at issuance date was $5,279 million . The increase in the amount since the date of issuance is due to foreign currency exchange. The following table provides the maturity schedule of our Long-term debt outstanding as of October 1, 2017: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 After 2021 Total Maturities $ 481 $ 4,825 $ 1,534 $ 4,502 $ 23,162 $ 34,503 E. Other Noncurrent Liabilities In August 2017, the U.S. approved Besponsa (inotuzumab ozogamicin) and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating $296 million related to a research and development arrangement. As a result, we have recorded the estimated net present value of $248 million as an intangible asset in Developed technology rights , and we have recorded $233 million in Other noncurrent liabilities and $15 million in Other current liabilities as of October 1, 2017. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a nine-year period aggregating $148 million related to a research and development arrangement. As a result, we recorded the estimated net present value of $123 million as an intangible asset in Developed technology rights , and we have recorded $117 million in Other noncurrent liabilities and $6 million in Other current liabilities as of October 1, 2017. F. Derivative Financial Instruments and Hedging Activities Foreign Exchange Risk As of October 1, 2017 , the aggregate notional amount of foreign exchange derivative financial instruments hedging or offsetting foreign currency exposures was $31.5 billion . The derivative financial instruments primarily hedge or offset exposures in the euro, Japanese yen and U.K. pound. The maximum length of time over which we are hedging future foreign exchange cash flow relates to our $2.0 billion U.K. pound debt maturing in 2038. We designate foreign currency forward-exchange contracts as cash flow hedges of a portion of our forecasted euro, Japanese yen, U.K. pound, Canadian dollar, and Australian dollar-denominated intercompany inventory sales expected to occur no more than two years from the date of each hedge. As of October 1, 2017 , the notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted sales was $3.9 billion , with a pre-tax loss of $97 million deferred in Accumulated other comprehensive loss. Based on quarter-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax loss of $63 million within the next 12 months into Cost of sales. We recognized a $4 million loss in the third quarter of 2017 and a $67 million gain in the first nine months of 2017 as an offset to Cost of sales . Interest Rate Risk As of October 1, 2017 , the aggregate notional amount of interest rate derivative financial instruments designated as fair value hedges was $12.4 billion . The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt. The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Three Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, October 1, October 2, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ 218 $ 87 $ 148 $ (39 ) Foreign currency forward-exchange contracts 1 2 (269 ) (212 ) (204 ) (111 ) Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts — — — — — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts 33 20 — — — — Foreign currency swaps — (4 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency long-term debt — — (166 ) — — — All other net — — 1 — — — $ 34 $ 18 $ (216 ) $ (126 ) $ (55 ) $ (150 ) Nine Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, October 1, October 2, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ 455 $ (204 ) $ 419 $ (165 ) Foreign currency forward-exchange contracts (5 ) 1 (604 ) (770 ) (26 ) (118 ) Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts — 1 — (15 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts (111 ) (49 ) — — — — Foreign currency swaps (1 ) (9 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — — (26 ) — — Foreign currency long-term debt — — (518 ) — — — All other net — — 1 1 — — $ (117 ) $ (56 ) $ (666 ) $ (1,014 ) $ 394 $ (283 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income. COS = Cost of sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships. (c) There was no significant ineffectiveness for any period presented. (d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income––Unrealized holding losses on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net. For information about the fair value of our derivative financial instruments, and the impact on our condensed consolidated balance sheets, see Note 7A above . Certain of our derivative instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce our counterparties’ exposure to our risk of defaulting on amounts owed. As of October 1, 2017 , the aggregate fair value of these derivative instruments that are in a net liability position was $491 million , for which we have posted collateral of $505 million in the normal course of business. If there had been a ratings downgrade, we would not have been required to post any additional collateral to our counterparties . G. Credit Risk On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty, except for certain significant customers. As of October 1, 2017 , we had $946 million due from a well-diversified, high quality group of technology companies around the world. For details about our investments, see Note 7B above. In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request collateral payments depending on levels of exposure, our credit rating and the credit rating of the counterparty. As of October 1, 2017 , we received cash collateral of $232 million from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in

Inventories

Inventories	9 Months Ended
	Oct. 01, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories The following table provides the components of Inventories : (MILLIONS OF DOLLARS) October 1, December 31, Finished goods $ 2,977 $ 2,293 Work-in-process 4,070 3,696 Raw materials and supplies 879 793 Inventories (a) $ 7,925 $ 6,783 Noncurrent inventories not included above (b) $ 669 $ 683 (a) The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand. (b) Included in Other noncurrent assets

Identifiable Intangible Assets

Identifiable Intangible Assets and Goodwill	9 Months Ended
	Oct. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Identifiable Intangible Assets and Goodwill	Identifiable Intangible Assets and Goodwill A. Identifiable Intangible Assets Balance Sheet Information The following table provides the components of Identifiable intangible assets : October 1, 2017 December 31, 2016 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,585 $ (53,960 ) $ 35,625 $ 83,390 $ (49,650 ) $ 33,740 Brands 2,135 (1,127 ) 1,008 2,092 (1,032 ) 1,060 Licensing agreements and other 1,930 (1,071 ) 859 1,869 (1,005 ) 864 93,650 (56,158 ) 37,492 87,351 (51,687 ) 35,664 Indefinite-lived intangible assets Brands and other 6,937 6,937 6,883 6,883 IPR&D (a) 5,292 5,292 10,101 10,101 12,229 12,229 16,984 16,984 Identifiable intangible assets (b) $ 105,879 $ (56,158 ) $ 49,721 $ 104,335 $ (51,687 ) $ 52,648 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A ) and (v) impairments of Developed technology rights (see Note 4) . (b) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A ), as well as impairments of Developed technology rights (see Note 4) , partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ). Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: October 1, 2017 IH EH WRD Developed technology rights 68 % 32 % — % Brands, finite-lived 75 % 25 % — % Brands, indefinite-lived 71 % 29 % — % IPR&D 80 % 13 % 7 % Amortization Total amortization expense for finite-lived intangible assets was $1.2 billion for the third quarter of 2017 and $988 million for the third quarter of 2016 , and $3.6 billion for the first nine months of 2017 and $3.0 billion for the first nine months of 2016 . B. Goodwill The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, December 31, 2016 $ 30,134 $ 24,315 $ 54,449 Additions (a) 572 92 664 Other (b) 491 475 966 Balance, October 1, 2017 $ 31,197 $ 24,882 $ 56,078 (a) IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see Note 2A ). (b)

Pension and Postretirement Bene

Pension and Postretirement Benefit Plans	9 Months Ended
	Oct. 01, 2017
Retirement Benefits [Abstract]
Pension and Postretirement Benefit Plans	Pension and Postretirement Benefit Plans The following table provides the components of net periodic benefit cost/(income): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Net periodic benefit cost/(credit): Service cost $ 67 $ 69 $ 6 $ 5 $ 44 $ 41 $ 10 $ 11 Interest cost 157 218 13 18 52 58 23 33 Expected return on plan assets (248 ) (239 ) — — (87 ) (95 ) (9 ) (8 ) Amortization of: Actuarial losses 91 99 12 9 29 23 8 9 Prior service costs (credits) — 1 — — (1 ) (1 ) (45 ) (45 ) Curtailments 1 2 — 1 (2 ) — (3 ) (8 ) Settlements 30 21 7 7 — 1 — — $ 99 $ 170 $ 39 $ 39 $ 35 $ 27 $ (17 ) $ (9 ) Nine Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Net periodic benefit cost/(credit): Service cost $ 202 $ 193 $ 18 $ 14 $ 127 $ 126 $ 32 $ 31 Interest cost 478 486 41 40 152 178 68 77 Expected return on plan assets (759 ) (721 ) — — (256 ) (291 ) (27 ) (25 ) Amortization of: Actuarial losses 302 297 37 27 86 70 23 23 Prior service costs (credits) 3 4 (1 ) (1 ) (3 ) (2 ) (137 ) (127 ) Curtailments 10 5 — 1 (2 ) (1 ) (15 ) (14 ) Settlements 54 52 32 23 3 2 — — $ 292 $ 316 $ 127 $ 105 $ 106 $ 81 $ (57 ) $ (36 ) (a) In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3 ). As of and for the nine months ended October 1, 2017 , we contributed and expect to contribute in 2017 from our general assets as follows: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the nine months ended October 1, 2017 $ 1,095 $ 121 $ 134 $ 158 Expected contributions from our general assets during 2017 (a) $ 1,095 $ 146 $ 170 $ 204 (a) Contributions expected to be made for 2017 are inclusive of amounts contributed during the nine months ended October 1, 2017 , including the $1.0 billion

Earnings Per Common Share Attri

Earnings Per Common Share Attributable to Common Shareholders	9 Months Ended
	Oct. 01, 2017
Earnings Per Share [Abstract]
Earnings Per Common Share Attributable to Common Shareholders	Earnings Per Common Share Attributable to Common Shareholders The following table provides the detailed calculation of Earnings per common share (EPS) : Three Months Ended Nine Months Ended (IN MILLIONS) October 1, October 2, October 1, October 2, EPS Numerator––Basic Income from continuing operations (a) $ 2,858 $ 1,355 $ 9,064 $ 6,465 Less: Net income attributable to noncontrolling interests 18 — 32 25 Income from continuing operations attributable to Pfizer Inc. (a) 2,840 1,355 9,032 6,440 Less: Preferred stock dividends––net of tax — — 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders (a) 2,839 1,355 9,032 6,439 Discontinued operations––net of tax — — 1 — Net income attributable to Pfizer Inc. common shareholders (a) $ 2,839 $ 1,355 $ 9,033 $ 6,439 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions (a) $ 2,840 $ 1,355 $ 9,032 $ 6,440 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — — 1 — Net income attributable to Pfizer Inc. common shareholders and assumed conversions (a) $ 2,840 $ 1,355 $ 9,034 $ 6,440 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,951 6,066 5,972 6,095 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (a) 89 84 85 80 Weighted-average number of common shares outstanding––Diluted (a) 6,041 6,150 6,057 6,175 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a), (b) 47 38 47 60 (a) Amounts for the third quarter and first nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016 , as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B ). (b)

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Oct. 01, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business. For a discussion of our tax contingencies, see Note 5B. Accelerated share repurchase agreement––On February 2, 2017, we entered into an accelerated share repurchase agreement with Citibank to repurchase $5 billion of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid $5 billion to Citibank and received an initial delivery of approximately 126 million shares of our common stock from Citibank at a price of $31.73 per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately 80% of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement’s settlement terms, we received an additional 24 million shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was $33.31 per share. The common stock received is included in Treasury Stock . This agreement was entered into pursuant to our previously announced share repurchase authorization. At October 1, 2017 , our remaining share-purchase authorization was approximately $6.4 billion . Pending approval in the EU of Mylotarg––Mylotarg was developed, in part, through a research arrangement with a third party. If Mylotarg is approved in the EU in 2018 for the treatment of acute myeloid leukemia, we will incur an obligation for additional fixed payments over a 10-year period aggregating $310 million . A. Legal Proceedings Our non-tax contingencies include, but are not limited to, the following: • Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the vast majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets. • Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters. • Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter. • Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other countries. Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, and/or criminal charges, which could be substantial. We believe that our claims and defenses in these matters are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid. We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader’s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote. A1. Legal Proceedings––Patent Litigation Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other countries. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering several of their products that may impact our licenses or co-promotion rights to such products. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio have been challenged in inter partes review and post-grant review proceedings in the United States. The invalidation of these patents could potentially allow a competitor pneumococcal vaccine into the marketplace. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our subsidiary, Hospira, is involved in patent and patent-related disputes over its attempts to bring generic pharmaceutical and biosimilar products to market. If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party. Actions In Which We Are The Plaintiff Bosulif (bosutinib) In December 2016, Wyeth LLC, Wyeth Pharmaceuticals Inc., and PF Prism C.V. (collectively, Wyeth) brought a patent-infringement action against Alembic Pharmaceuticals, Ltd, Alembic Pharmaceuticals, Inc. (collectively, Alembic), Sun Pharmaceutical Industries, Inc., and Sun Pharmaceutical Industries Limited (collectively, Sun), in the U.S. District Court for the District of Delaware in connection with abbreviated new drug applications respectively filed with the FDA by Alembic and Sun, each seeking approval to market generic versions of bosutinib. Alembic is challenging patents, which expire in 2026, covering polymorphic forms of bosutinib and methods of treating chronic myelogenous leukemia. Sun is challenging the patent covering polymorphic forms of bosutinib that expires in 2026. In March 2017, Wyeth brought a patent-infringement action against MSN Laboratories Private Limited and MSN Pharmaceuticals, Inc. (collectively, MSN), in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed with the FDA by MSN, seeking approval to market a generic version of bosutinib, and challenging a patent expiring in 2026 covering polymorphic forms of bosutinib. In September 2017, the case against MSN was dismissed. Also, in September 2017, Wyeth brought an additional patent-infringement action against Sun in the U.S. District Court for the District of Delaware asserting the infringement and validity of two other patents challenged by Sun, which expire in 2025 and 2026 respectively, covering compositions of bosutinib and methods of treating chronic myelogenous leukemia. EpiPen In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz’s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name. Flector Patch (diclofenac) In October 2015, the owners (Teikoku Seiyaku Co., Ltd. and Altergon SA) of a patent covering Pfizer’s Flector Patch product, along with the New Drug Application holder (IBSA Institut Biochemique SA), brought a patent-infringement action against Actavis Laboratories UT, Inc. in the U.S. District Court for the District of Delaware in connection with an abbreviated new drug application filed by Actavis Laboratories UT, Inc. with the FDA requesting approval to launch a generic version of Flector Patch prior to the 2019 expiration of the patent. In August 2016, Pfizer subsidiary Alpharma Pharmaceuticals LLC was added as a plaintiff to the lawsuit. In August 2017, this case was settled on terms not material to Pfizer. Precedex Premix In June 2014, Ben Venue Laboratories, Inc. (Ben Venue) notified our subsidiary, Hospira, that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that a patent relating to the use of Precedex in an intensive care unit setting, which expires in March 2019, was invalid or not infringed. In August 2014, Hospira and Orion Corporation (co-owner of the patent that is the subject of the lawsuit) filed suit against Ben Venue, Hikma Pharmaceuticals PLC (Hikma), and West-Ward Pharmaceutical Corp. in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patent that is the subject of the lawsuit. In October 2014, Eurohealth International Sarl was substituted for Ben Venue and Hikma. In June 2016, this case was settled on terms not material to Pfizer. In June 2015, Amneal Pharmaceuticals LLC (Amneal) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In August 2015, Hospira filed suit against Amneal in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois asserting the validity and infringement of the patents that are the subject of the lawsuit. In August 2016, Par Sterile Products, LLC (Par) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira’s premix version of Precedex and containing allegations that four patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In September 2016, Hospira filed suit against Par in the U.S. District Court for the District of Delaware asserting the validity and infringement of the patents that are the subject of the lawsuit. In December 2016, the case was stayed pending the outcome of Hospira’s suit against Amneal (including all appeals). Toviaz (fesoterodine) We have an exclusive, worldwide license to market Toviaz from UCB Pharma GmbH (UCB), which owns the patents relating to Toviaz. Beginning in May 2013, several generic drug manufacturers notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the FDA’s list of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly referred to as the “Orange Book”. Beginning in June 2013, we filed actions against all of those generic drug manufacturers in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In June and July 2015, we settled with four of the generic defendants. The trial relating to the four remaining defendants occurred in July 2015. In April 2016, the District Court held that the patents that were the subject of the lawsuit were valid and infringed. The defendants’ deadline to appeal this decision expired in June 2016. In December 2014, Mylan Pharmaceuticals, Inc. (Mylan Pharmaceuticals) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In January 2015, we filed an action against Mylan Pharmaceuticals in the U.S. District Court for the District of Delaware, asserting the infringement of five of the patents for Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. In January 2017, the District Court issued a verdict finding that the five patents that are the subject of the lawsuit are valid and infringed. In August 2017, the District Court issued a written decision consistent with the verdict, finding the five patents valid and infringed. In September 2017, Mylan Pharmaceuticals appealed the District Court’s decision to the U.S. Court of Appeals for the Federal Circuit. In December 2016, Torrent Pharmaceuticals, Ltd. (Torrent) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Toviaz and asserting the invalidity, unenforceability and/or non-infringement of all of our patents for Toviaz that are listed in the Orange Book. In February 2017, we filed an action against Torrent in the U.S. District Court for the District of Delaware, asserting the infringement of the same five patents that are the subject of the action against Mylan Pharmaceuticals. In September 2017, this case was dismissed. Xeljanz (tofacitinib) In February 2017, we brought a patent-infringement action against MicroLabs USA Inc. and MicroLabs Ltd. (collectively, MicroLabs) in the U.S. District Court for the District of Delaware asserting the infringement and validity of three patents challenged by MicroLabs in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Of the three patents that are the subject of the lawsuit, one covers the active ingredient and expires in December 2025, the second covers an enantiomer of tofacitinib and expires in 2022, and the third covers a polymorphic form of tofacitinib and expires in 2023. Three other patents for Xeljanz expiring in December 2020 have not been challenged by MicroLabs. Separately, also in February 2017, we brought a patent-infringement action against Sun Pharmaceutical Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering a polymorphic form of tofacitinib, expiring in 2023, that was challenged by Sun Pharmaceutical Industries Ltd. in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets. In November 2017, we brought an additional patent-infringement action against Sun Pharmaceuticals Industries Ltd. in the U.S. District Court for the District of Delaware asserting the infringement and validity of another patent challenged by Sun Pharmaceuticals Industries Ltd, which covers the active ingredient and expires in December 2025. In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of the same three patents that are the subject of the action against MicroLabs, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. Also in March 2017, we brought separate actions in the U.S. District Court for the District of Delaware against Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC (collectively Prinston) and against Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. (collectively Breckenridge) on the two patents expiring in 2022 and 2023, respectively, that were challenged by Prinston and Breckenridge in their respective abbreviated new drug applications seeking approval to market generic versions of tofacitinib 5 mg tablets. In October 2017, we brought an additional patent-infringement action against Breckenridge in the U.S. District Court for the District of Delaware asserting the infringement and validity of four additional patents challenged by Breckenridge, three of which expire in December 2020 and one of which expires in December 2025. Xtandi (enzalutamide) In December 2016, Medivation and Medivation Prostate Therapeutics, Inc. (collectively, the Medivation Group); Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc. (collectively, Astellas); and The Regents of the University of California filed patent-infringement suits in the U.S. District Court for the District of Delaware against Actavis Laboratories FL, Inc. and Actavis LLC (collectively, Actavis); Zydus; and Apotex Inc. and Apotex Corp. (collectively, Apotex) in connection with those companies’ respective abbreviated new drug applications filed with the FDA for approval to market generic versions of enzalutamide. The generic manufacturers are challenging patents, which expire as early as 2026, covering enzalutamide and treatments for prostate cancer. In May 2017, the Medivation Group filed a patent-infringement suit against Roxane Laboratories Inc. (Roxane) in the same court in connection with Roxane’s abbreviated new drug application with the FDA for approval to market a generic version of enzalutamide. Matters Involving Our Collaboration/Licensing Partners Nexium 24HR (esomeprazole) We have an exclusive license from AstraZeneca PLC (AstraZeneca) to market in the U.S. the OTC version of Nexium (Nexium 24HR). Between October 2014 and November 2016, Actavis Laboratories FL, Inc. (Actavis), Andrx Labs, LLC (Andrx), Perrigo Company plc (Perrigo), Lupin Limited, Dr. Reddy’s Laboratories, Inc. & Ltd. (Dr. Reddy’s), Hetero USA Inc. (Hetero), Aurobindo Pharma USA Inc. (Aurobindo) and Cipla Limited (Cipla) notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Nexium 24HR prior to the expiration of one or more of AstraZeneca’s patents listed in the Orange Book for Nexium 24HR. AstraZeneca filed actions against each of these companies in the U.S. District Court for the District of New Jersey asserting infringement of the challenged patents. In March 2017, the cases against Actavis and Andrx were settled on terms not material to Pfizer. In June 2017, the cases against Perrigo, Dr. Reddy’s and Lupin Limited were settled on terms not material to Pfizer. In August 2017, the cases against Hetero and Aurobindo were settled on terms not material to Pfizer. In October 2017, AstraZeneca’s action against Cipla was settled on terms not material to Pfizer. We were not a party to AstraZeneca’s patent-infringement actions. Toviaz (fesoterodine)––Inter-Partes Reviews In January 2016, Mylan Pharmaceuticals and Mylan Laboratories (collectively, Mylan) filed petitions with the U.S. Patent and Trademark Office requesting inter partes reviews of five of the patents covering fesoterodine, the active ingredient in Toviaz: three composition-of-matter patents and a method-of-use patent that expire in 2019 and a patent covering salts of fesoterodine that expires in 2022. The patents are owned by UCB, and we have an exclusive, worldwide license to market Toviaz from UCB. In July 2016, the Patent Trial and Appeal Board agreed to institute inter partes reviews of all five patents. Amerigen Pharmaceuticals Limited (Amerigen), Alembic Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have joined the inter partes reviews. In July 2017, the U.S. Patent and Trademark Office issued decisions upholding all five patents. In September 2017, Mylan and Amerigen appealed the U.S. Patent and Trademark Office decisions to the U.S. Court of Appeals for the Federal Circuit . Eliquis In February, March, and April 2017, twenty-five generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the three patents listed in the Orange Book for Eliquis. The patents currently are set to expire in 2019, 2026, and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies’ proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all three patents. Bavencio (avelumab) In July 2017, BMS, E.R. Squibb & Sons LLC, Ono Pharmaceutical Co. Ltd., and Tasuku Honjo brought a patent-infringement action in the U.S. District Court for the District of Delaware against Pfizer, Merck KGaA, and EMD Serono, alleging that Bavencio (avelumab) infringes one patent relating to methods for treating tumors with anti-PD-L1 antibodies, which expires in 2023. Actions In Which We Are The Defendant Inflectra (infliximab-dyyb) In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe six patents relating to infliximab, its manufacture and use. Claims with respect to four of the patents have since been dismissed by the plaintiffs, leaving two patents at issue in the ongoing action: the infliximab antibody patent and a patent relating to cell culture media. In August 2016, the U.S. District Court for the District of Massachusetts ruled that the antibody patent was invalid, and Janssen has appealed that ruling to the Court of Appeals for the Federal Circuit. A2. Legal Proceedings––Product Litigation Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss. Asbestos Between 1967 and 1982, Warner-Lambert owned American Optical Corporation, which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. As of October 1, 2017 , approximately 56,500 claims naming American Optical and numerous other defendants were pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly-owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims. Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries. There also are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries. Effexor • Personal Injury Actions A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Effexor. Among other types of actions, the Effexor personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Effexor by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages. In August 2013, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Effexor ( Venlafaxine Hydrochloride) Products Liability Litigation MDL-2458 ) in the U.S. District Court for the Eastern District of Pennsylvania. Almost all plaintiffs have voluntarily dismissed their actions. The Multi-District Litigation, as well as the coordinated state court proceedings in California, has been administratively stayed. • Antitrust Actions Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants’ allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. In October 2014, the District Court dismissed the direct purchaser plaintiffs’ claims based on the litigation settlement agreement but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court’s decisions and remanded the claims to the District Court. Zoloft A number of individual lawsuits and multi-plaintiff lawsuits have been filed against us and/or our subsidiaries in various federal and state courts alleging personal injury as a result of the purported ingestion of Zoloft. Among other types of actions, the Zoloft personal injury litigation includes actions alleging a variety of birth defects as a result of the purported ingestion of Zoloft by women during pregnancy. Plaintiffs in these birth-defect actions seek compensatory and punitive damages and the disgorgement of profits resulting from the sale of Zoloft. In April 2012, the federal birth-defect cases were transferred for consolidated pre-trial proceedings to a Multi-District Litigation ( In re Zoloft Products Liability Litigation MDL-2342 ) in the U.S. District Court for the Eastern District of Pennsylvania. A number of plaintiffs have voluntarily dismissed their actions. In April 2016, the District Court granted our motion for summary judgment, dismissing the claims of almost all of the remaining plaintiffs. In May 2016, the plaintiffs appealed the District Court’s decision to the U.S. Court of Appeals for the Third Circuit. In June 2017, the U.S. Court of Appeals for the Third Ci

Segment, Geographic and Other R

Segment, Geographic and Other Revenue Information	9 Months Ended
	Oct. 01, 2017
Segment Reporting [Abstract]
Segment, Geographic and Other Revenue Information	Segment, Geographic and Other Revenue Information A. Segment Information We manage our commercial operations through two distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH and EH segments are each led by a single manager. Each operating segment has responsibility for its commercial activities and for certain IPR&D projects for new investigational products and additional indications for in-line products that generally have achieved proof-of-concept. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the two operating segments, among other factors, for performance evaluation and resource allocation. We regularly review our segments and the approach used by management for performance evaluation and resource allocation. As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 and 2016. Operating Segments Some additional information about our business segments follows: IH Segment EH Segment IH focuses on developing and commercializing novel, value-creating medicines and vaccines that significantly improve patients’ lives, as well as products for consumer healthcare. EH includes legacy brands that have lost or will soon lose market exclusivity in both developed and emerging markets, branded generics, generic sterile injectable products, biosimilars, select branded products including anti-infectives and, through February 2, 2017, HIS. EH also includes an R&D organization, as well as our contract manufacturing business. Leading brands include: - Prevnar 13/Prevenar 13 - Xeljanz - Eliquis - Lyrica (U.S., Japan and certain other markets) Enbrel (outside the U.S. and Canada) Viagra (U.S. and Canada) Ibrance - Xtandi - Several OTC consumer healthcare products (e.g., Advil and Centrum ) Leading brands include: - Lipitor - Premarin family - Norvasc - Lyrica (Europe, Russia, Turkey, Israel and Central Asia countries) - Celebrex - Inflectra/Remsima - Several sterile injectable products Other Costs and Business Activities Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following: • WRD, which is generally responsible for research projects for our IH business until proof-of-concept is achieved and then for transitioning those projects to the IH segment via the GPD organization for possible clinical and commercial development. R&D spending may include upfront and milestone payments for intellectual property rights. The WRD organization also has responsibility for certain science-based and other platform-services organizations, which provide technical expertise and other services to the various R&D projects, including EH R&D projects. WRD is also responsible for facilitating all regulatory submissions and interactions with regulatory agencies, including all safety-event activities. • GPD, which is generally responsible for the clinical development of assets that are in clinical trials for our WRD and Innovative portfolios. GPD also provides technical support and other services to Pfizer R&D projects. • Corporate, representing platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement) and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments. Effective in the first quarter of 2017 , Corporate also includes the costs associated with our Pfizer Medical organization (Medical), previously reported as part of Other Business Activities. Medical is responsible for the provision of medical information to healthcare providers, patients and other parties, transparency and disclosure activities, clinical trial results publication, grants for healthcare quality improvement and medical education, and partnerships with global public health and medical associations. • Other unallocated costs, representing overhead expenses associated with our manufacturing and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs (which include manufacturing variances associated with production). • Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities. Segment Assets We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared (such as our plant network assets) or commingled (such as accounts receivable, as many of our customers are served by both operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately $172 billion as of October 1, 2017 and December 31, 2016 . Selected Income Statement Information The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Reportable Segments: IH $ 8,118 $ 7,332 $ 4,875 $ 4,187 EH 5,050 5,712 2,765 3,128 Total reportable segments 13,168 13,045 7,640 7,315 Other business activities (b), (c) — — (759 ) (753 ) Reconciling Items: Corporate (c) — — (1,382 ) (1,537 ) Purchase accounting adjustments (c) — — (1,154 ) (966 ) Acquisition-related costs (c) — — (155 ) (280 ) Certain significant items (d) — — (449 ) (1,969 ) Other unallocated — — (156 ) (206 ) $ 13,168 $ 13,045 $ 3,585 $ 1,604 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Reportable Segments: IH $ 23,204 $ 21,471 $ 14,190 $ 12,470 EH 15,639 17,725 8,558 9,985 Total reportable segments 38,843 39,196 22,748 22,454 Other business activities (b), (c) — — (2,205 ) (2,096 ) Reconciling Items: Corporate (c) — — (3,948 ) (4,217 ) Purchase accounting adjustments (c) — — (3,527 ) (3,103 ) Acquisition-related costs (c) — — (347 ) (598 ) Certain significant items (d) — — (797 ) (4,112 ) Other unallocated — — (573 ) (753 ) $ 38,843 $ 39,196 $ 11,351 $ 7,575 (a) Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million , respectively, from our investment in ViiV. For additional information, see Note 4. (b) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $33 million and $94 million of costs from Other Business Activities to Corporate in the third quarter and first nine months of 2016 , respectively, to conform to the current period presentation. (c) For a description, see the “Other Costs and Business Activities” section above. (d) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $90 million , (ii) charges for certain legal matters of $183 million , (iii) income of $12 million , representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $45 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $253 million , (ii) charges for certain legal matters of $191 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $52 million , (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $54 million and (vi) other charges of $119 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 3 and Note 4 . Equity in the net income of investees accounted for by the equity method is not significant for any of our operating segments. The operating segment information does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented. B. Geographic Information As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 and 2016. The following table provides revenues by geographic area: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, % Change October 1, October 2, % Change U.S. $ 6,534 $ 6,530 — $ 19,516 $ 19,561 — Developed Europe (a) 2,163 2,218 (2 ) 6,309 6,982 (10 ) Developed Rest of World (b) 1,632 1,711 (5 ) 4,797 4,940 (3 ) Emerging Markets (c) 2,839 2,586 10 8,222 7,714 7 Revenues $ 13,168 $ 13,045 1 $ 38,843 $ 39,196 (1 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the third quarter of 2017 and 2016 , and $5.0 billion and $5.3 billion in the first nine months of 2017 and 2016 , respectively. (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey. C. Other Revenue Information Significant Product Revenues As described in Note 1A , acquisitions and divestitures have impacted our results of operations in 2017 and 2016. The following table provides detailed revenue information: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, PFIZER INNOVATIVE HEALTH (IH) (a) $ 8,118 $ 7,332 $ 23,204 $ 21,471 Internal Medicine $ 2,455 $ 2,243 $ 7,245 $ 6,557 Lyrica IH (b) 1,150 1,049 3,382 3,107 Eliquis alliance revenues and direct sales 644 449 1,813 1,225 Chantix/Champix 240 198 727 631 Viagra IH (c) 206 297 711 897 BMP2 79 63 198 175 Toviaz 62 60 187 191 All other Internal Medicine 75 128 228 330 Vaccines $ 1,649 $ 1,641 $ 4,385 $ 4,576 Prevnar 13/Prevenar 13 1,522 1,536 4,069 4,302 FSME/IMMUN-TicoVac 43 33 119 102 All other Vaccines 85 72 197 172 Oncology $ 1,616 $ 1,104 $ 4,551 $ 3,206 Ibrance 878 550 2,410 1,492 Sutent 276 260 805 823 Xalkori 146 140 442 415 Xtandi alliance revenues 150 2 422 2 Inlyta 84 95 256 304 Bosulif 57 43 163 121 All other Oncology 26 15 54 49 Inflammation & Immunology (I&I) $ 1,000 $ 960 $ 2,863 $ 2,907 Enbrel (Outside the U.S. and Canada) 613 701 1,818 2,201 Xeljanz 348 235 935 649 Eucrisa 15 — 33 — All other I&I 23 24 78 57 Rare Disease $ 569 $ 585 $ 1,637 $ 1,768 BeneFIX 151 176 453 543 Refacto AF/Xyntha 140 140 409 408 Genotropin 136 147 375 425 Somavert 65 59 182 173 All other Rare Disease 77 64 218 219 Consumer Healthcare $ 829 $ 798 $ 2,522 $ 2,457 PFIZER ESSENTIAL HEALTH (EH) (d) $ 5,050 $ 5,712 $ 15,639 $ 17,725 Legacy Established Products (LEP) (e) $ 2,681 $ 2,708 $ 7,995 $ 8,373 Lipitor 491 422 1,341 1,294 Premarin family 238 244 711 751 Norvasc 226 238 684 714 EpiPen 82 110 253 300 Xalatan/Xalacom 83 91 241 273 Effexor 76 70 215 207 Zoloft 78 72 215 228 Zithromax 61 56 202 203 Relpax 50 83 193 248 Xanax 58 55 164 163 All other LEP 1,237 1,268 3,776 3,992 Sterile Injectable Pharmaceuticals (SIP) (f) $ 1,273 $ 1,461 $ 4,270 $ 4,481 Medrol 109 102 352 330 Sulperazon 114 102 345 304 Fragmin 79 80 221 240 Tygacil 60 69 192 203 Precedex 51 64 182 199 All other SIP 860 1,044 2,977 3,206 Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Peri-LOE Products (g) $ 794 $ 1,023 $ 2,398 $ 3,224 Celebrex 212 194 564 550 Lyrica EH (b) 134 191 428 623 Vfend 97 140 305 459 Viagra EH (c) 102 89 285 286 Pristiq 69 174 230 546 Zyvox 68 94 220 334 Revatio 58 73 189 213 All other Peri-LOE Products 55 68 176 214 Biosimilars (h) $ 141 $ 83 $ 367 $ 228 Inflectra/Remsima 112 49 284 130 All other Biosimilars 28 34 82 97 Pfizer CentreOne (i) $ 161 $ 156 $ 514 $ 540 Hospira Infusion Systems (HIS) (j) $ — $ 281 $ 97 $ 879 Revenues $ 13,168 $ 13,045 $ 38,843 $ 39,196 Total Lyrica (b) $ 1,285 $ 1,240 $ 3,810 $ 3,730 Total Viagra (c) $ 308 $ 387 $ 996 $ 1,183 Total Alliance revenues $ 741 $ 419 $ 2,112 $ 1,155 (a) The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations. (e) Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above. (f) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (g) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. (h) Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. (i) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. (j)

Basis of Presentation and Sig22

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Oct. 01, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation See the Glossary of Defined Terms at the beginning of this Quarterly Report on Form 10-Q for terms used throughout the condensed consolidated financial statements and related notes of this Quarterly Report on Form 10-Q. We prepared the condensed consolidated financial statements following the requirements of the SEC for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. The financial information included in our condensed consolidated financial statements for subsidiaries operating outside the U.S. is as of and for the three and nine months ended August 27, 2017 and August 28, 2016 . The financial information included in our condensed consolidated financial statements for U.S. subsidiaries is as of and for the three and nine months ended October 1, 2017 and October 2, 2016 . Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year. We are responsible for the unaudited financial statements included in this Quarterly Report on Form 10-Q. The interim financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of our condensed consolidated balance sheets and condensed consolidated statements of income. The information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2016
Adoption of New Accounting Standards	Adoption of New Accounting Standards In the fourth quarter of 2016, we adopted a new accounting standard for certain elements of the accounting for share-based payments as of January 1, 2016. Specifically, the new standard requires excess tax benefits or deficiencies (including tax benefits of dividend equivalents) of share-based compensation to be recognized as a component of the Provision for taxes on income , whereas excess tax benefits or deficiencies previously were recognized in Additional paid-in capital . The net tax benefit for the Company was $35 million for the third quarter of 2016 and $85 million for the first nine months of 2016 . Also, in the diluted net earnings per share calculation, when applying the treasury stock method for shares that could be repurchased, the assumed proceeds no longer include the amount of excess tax benefit. Another element of the new accounting standard requires that we now present excess tax benefits as operating activities in our consolidated statement of cash flows. We elected to adopt this presentation on a prospective basis as of January 1, 2016. Additionally, cash paid by us when directly withholding shares for tax-withholding purposes is now a cash outflow from financing activities. This reclassification was required to be adopted retrospectively. As a result, $87 million of cash outflows for the first nine months of 2016 was reclassified from operating activities to financing activities in the condensed consolidated statement of cash flows. For additional information, see Notes to Consolidated Financial Statements–– Note 1B. Basis of Presentation and Significant Accounting Policies : Adoption of New Accounting Standards included in our 2016 Financial Report. We adopted a new standard as of January 1, 2017 that amended guidance on the assessment of whether an entity is the primary beneficiary of a variable interest entity. Under this new guidance, when evaluating whether an entity is the primary beneficiary, a single decision maker must consider its indirect interest held through related parties under common control proportionately. There was no material impact to our condensed consolidated financial statements from adopting this standard.

Restructuring Charges and Oth23

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)	9 Months Ended
	Oct. 01, 2017
Restructuring and Related Activities [Abstract]
Schedule of Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives	The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Restructuring charges (a) : Employee terminations $ (20 ) $ 347 $ 9 $ 464 Asset impairments (b) 101 27 126 45 Exit costs 10 29 16 64 Total restructuring charges 91 404 150 574 Transaction costs (c) (14 ) 54 4 114 Integration costs (d) 73 74 224 300 Restructuring charges and certain acquisition-related costs 149 531 377 988 Additional depreciation––asset restructuring recorded in our condensed consolidated statements of income as follows (e) : Cost of sales 39 46 74 145 Research and development expenses — 1 — 5 Total additional depreciation––asset restructuring 39 47 74 151 Implementation costs recorded in our condensed consolidated statements of income as follows (f) : Cost of sales 26 46 77 127 Selling, informational and administrative expenses 22 23 46 56 Research and development expenses 9 8 26 17 Other (income)/deductions––net — 1 — 2 Total implementation costs 57 78 150 202 Total costs associated with acquisitions and cost-reduction/productivity initiatives $ 245 $ 655 $ 601 $ 1,341 (a) In the third quarter and first nine months of 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the third quarter and first nine months of 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first nine months ended October 1, 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities for 2017 are associated with the following: • For the third quarter of 2017 , IH ( $4 million ); EH ( $1 million ); WRD/GPD ( $15 million ); manufacturing operations ( $47 million ); and Corporate ( $25 million ). • For the first nine months of 2017 , IH ( $10 million ); EH ( $9 million income); WRD/GPD ( $29 million ); manufacturing operations ( $70 million ); and Corporate ( $51 million ). The restructuring activities for 2016 are associated with the following: • For the third quarter of 2016 , IH ( $148 million ); EH ( $28 million ); WRD/GPD ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million ). (b) The asset impairment charges for the third quarter and the first nine months of 2017 are largely associated with our acquisitions of Hospira and Medivation. (c) Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the third quarter of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the first nine months of 2017 are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the third quarter of 2016 were mostly related to the Medivation acquisition, and in the first nine months of 2016 , were mostly related to the Medivation and Anacor acquisitions, and our terminated transaction with Allergan. (d) Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter and first nine months of 2017 , integration costs primarily relate to our acquisitions of Hospira and Medivation. The first nine months of 2017 also include a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10 ). In the third quarter of 2016 , integration costs were mostly related to our acquisition of Hospira, and in the first nine months of 2016 , integration costs were mostly related to our acquisition of Hospira and our terminated transaction with Allergan. (e) Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions. (f)
Schedule of Components of and Changes in Restructuring Accruals	The following table provides the components of and changes in our restructuring accruals: (MILLIONS OF DOLLARS) Employee Termination Costs Asset Impairment Charges Exit Costs Accrual Balance, December 31, 2016 (a) $ 1,547 $ — $ 36 $ 1,583 Provision 9 126 16 150 Utilization and other (b) (401 ) (126 ) (24 ) (551 ) Balance, October 1, 2017 (c) $ 1,154 $ — $ 28 $ 1,182 (a) Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million ). (b) Includes adjustments for foreign currency translation. (c) Included in Other current liabilities ( $533 million ) and Other noncurrent liabilities ( $650 million

Other (Income)_Deductions - N24

Other (Income)/Deductions - Net (Tables)	9 Months Ended
	Oct. 01, 2017
Other Income and Expenses [Abstract]
Schedule of Other (Income)/Deductions - Net	The following table provides components of Other (income)/deductions––net : Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Interest income (a) $ (99 ) $ (123 ) $ (275 ) $ (357 ) Interest expense (a) 320 291 940 889 Net interest expense 220 168 666 532 Royalty-related income (b) (140 ) (233 ) (331 ) (695 ) Certain legal matters, net (c) 183 (40 ) 194 494 Net gains on asset disposals (d) (155 ) (47 ) (349 ) (81 ) Loss on sale and impairment on remeasurement of HIS net assets (e) (12 ) 1,422 52 1,422 Certain asset impairments (f) 130 133 143 1,080 Business and legal entity alignment costs (g) 16 69 54 180 Other, net (h) (191 ) (55 ) (445 ) (117 ) Other (income)/deductions––net $ 51 $ 1,417 $ (16 ) $ 2,815 (a) Interest income decreased in the third quarter and first nine months of 2017 , primarily driven by a lower investment balance. Interest expense increased in the third quarter and first nine months of 2017 , primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt . (b) Royalty-related income decreased in the third quarter and first nine months of 2017 , primarily due to lower royalty income for Enbrel of $139 million and $414 million , respectively, resulting from the expiration on October 31, 2016 of the 36 -month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $73 million and $160 million , respectively. (c) In the third quarter and first nine months of 2017 , primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a $79 million charge to reflect damages awarded by a jury in a patent matter. In the first nine months of 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the first nine months of 2016 includes a settlement related to a patent matter. (d) In the third quarter of 2017 , primarily includes gains on sales/out-licensing of product and compound rights (approximately $71 million ) and gains on sales and redemptions of investments in equity and debt securities (approximately $66 million ). In the first nine months of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $183 million ), gains on sales/out-licensing of product and compound rights (approximately $141 million ) and a gain on sale of property (approximately $52 million ), partially offset by a net loss related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest (approximately $30 million ). In the first nine months of 2016 , includes gains on sales/out-licensing of product and compound rights (approximately $49 million ). (e) In the third quarter and first nine months of 2017 , represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. (f) In the third quarter and first nine months of 2017 , primarily includes an intangible asset impairment charge of $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the third quarter and first nine months of 2017 is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the third quarter of 2016 , primarily includes intangible asset impairment charges of $126 million , reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ( $97 million ) and IH ( $29 million ). In the first nine months of 2016 , primarily includes intangible asset impairment charges of $767 million , reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ( $738 million ) and IH ( $29 million ). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer’s 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D. The intangible asset impairment charge for 2016 for the IPR&D compound for the treatment of anemia acquired in connection with our acquisition of Hospira reflects, among other things, the impact of regulatory delays, including delays resulting from a court ruling, which required a 180-day waiting period after approval before a biosimilar product can be launched. The intangible asset impairment charges for 2016 for the sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma reflect, among other things, the impact of portfolio prioritization decisions and decreased commercial profiles of certain compounds. The intangible asset impairment charges for 2016 for developed technology rights and other IPR&D assets acquired in connection with our acquisition of Hospira reflect, among other things, the impact of new scientific findings, updated commercial forecasts, changes in pricing, and an increased competitive environment. The intangible asset impairment charges for 2016 for other IPR&D assets acquired in connection with our acquisition of King reflect changes in the competitive environment. (g) In the third quarter and first nine months of 2017 and 2016 , represents expenses for changes to our infrastructure to align our commercial operations, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business. (h) In the third quarter and first nine months of 2017 , includes, among other things, dividend income of $54 million and $211 million , respectively, from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In the first nine months of 2016 , includes, among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction and income of $116 million
Schedule of Impaired Intangible Assets	The following table provides additional information about the intangible assets that were impaired during 2017 in Other (income)/deductions––net : Fair Value (a) Nine Months Ended October 1, 2017 (MILLIONS OF DOLLARS) Amount Level 1 Level 2 Level 3 Impairment Intangible assets –– Developed technology rights (b) $ 50 $ — $ — $ 50 $ 127 (a) The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. (b) Reflects intangible assets written down to fair value in the third quarter of 2017

Tax Matters (Tables)

Tax Matters (Tables)	9 Months Ended
	Oct. 01, 2017
Income Tax Disclosure [Abstract]
Schedule of Tax Provision (Benefit) on Other Comprehensive Income/(Loss)	The following table provides the components of Tax provision/(benefit) on other comprehensive income: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Foreign currency translation adjustments, net (a) $ (62 ) $ — $ (192 ) $ (15 ) Unrealized holding losses on derivative financial instruments, net 28 — 30 (192 ) Reclassification adjustments for realized (gains)/losses (29 ) 32 (169 ) 81 (1 ) 32 (139 ) (112 ) Unrealized holding gains on available-for-sale securities, net 37 40 93 106 Reclassification adjustments for realized gains (49 ) (14 ) (45 ) (16 ) (12 ) 26 47 90 Benefit plans: actuarial losses, net (37 ) (31 ) (15 ) (39 ) Reclassification adjustments related to amortization 60 47 152 140 Reclassification adjustments related to settlements, net 22 10 30 27 Other (33 ) 14 (46 ) 5 11 40 121 133 Benefit plans: prior service (costs)/credits and other, net — 35 — 66 Reclassification adjustments related to amortization (17 ) (17 ) (50 ) (47 ) Reclassification adjustments related to curtailments, net (1 ) (3 ) (5 ) (5 ) Other 1 2 1 1 (17 ) 18 (55 ) 15 Tax provision/(benefit) on other comprehensive income $ (80 ) $ 116 $ (218 ) $ 111 (a)

Accumulated Other Comprehensi26

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)	9 Months Ended
	Oct. 01, 2017
Equity [Abstract]
Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax	The following table provides the changes, net of tax, in Accumulated other comprehensive loss : Net Unrealized Gains/(Losses) Benefit Plans (MILLIONS OF DOLLARS) Foreign Currency Translation Adjustments Derivative Financial Instruments Available-For-Sale Securities Actuarial Gains/(Losses) Prior Service (Costs)/Credits and Other Accumulated Other Comprehensive Income/(Loss) Balance, December 31, 2016 $ (6,659 ) $ 348 $ (131 ) $ (5,473 ) $ 879 $ (11,036 ) Other comprehensive income/(loss) (a) 1,638 (403 ) 470 263 (96 ) 1,872 Balance, October 1, 2017 $ (5,021 ) $ (55 ) $ 339 $ (5,210 ) $ 783 $ (9,164 ) (a) Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $16 million income for the first nine months of 2017

Financial Instruments (Tables)

Financial Instruments (Tables)	9 Months Ended
	Oct. 01, 2017
Financial Instruments [Abstract]
Information about Certain Financial Assets and Liabilities	The following table provides additional information about certain of our financial assets and liabilities: (MILLIONS OF DOLLARS) October 1, December 31, Selected financial assets measured at fair value on a recurring basis (a) Trading funds and securities (b) $ 347 $ 325 Available-for-sale debt securities (c) 16,598 18,632 Money market funds 1,824 1,445 Available-for-sale equity securities (c) 1,032 540 Derivative financial instruments in a receivable position (d) : Interest rate swaps 630 625 Foreign currency swaps 92 79 Foreign currency forward-exchange contracts 110 551 20,631 22,198 Other selected financial assets Held-to-maturity debt securities, carried at amortized cost (c), (e) 1,464 1,242 Restricted stock and private equity securities, carried at cost or at equity-method (e) 719 735 2,183 1,977 Total selected financial assets $ 22,815 $ 24,175 Selected financial liabilities measured at fair value on a recurring basis (a) Derivative financial instruments in a liability position (f) : Interest rate swaps $ 154 $ 148 Foreign currency swaps 710 1,374 Foreign currency forward-exchange contracts 309 143 1,173 1,665 Other selected financial liabilities Short-term borrowings: Principal amount 9,460 10,674 Net fair value adjustments related to hedging and purchase accounting 2 24 Net unamortized discounts, premiums and debt issuance costs (15 ) (11 ) Total short-term borrowings, carried at historical proceeds, as adjusted (e) 9,448 10,688 Long-term debt: Principal amount 33,671 30,529 Net fair value adjustments related to hedging and purchase accounting 981 998 Net unamortized discounts, premiums and debt issuance costs (149 ) (130 ) Total long-term debt, carried at historical proceeds, as adjusted (g) 34,503 31,398 43,951 42,085 Total selected financial liabilities $ 45,124 $ 43,750 (a) We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except 5% that use Level 1 inputs. (b) As of October 1, 2017 , trading funds and securities are composed of $274 million of trading equity funds and $74 million of trading debt funds. As of December 31, 2016 , trading funds and securities are composed of $236 million of trading equity funds and $89 million of trading debt funds. As of October 1, 2017 and December 31, 2016 , trading equity funds of $63 million and $71 million , respectively, are held in trust for benefits attributable to the former Pharmacia Savings Plus Plan. (c) Gross unrealized gains and losses are not significant, except as of October 1, 2017 , available-for-sale equity securities’ unrealized gains are $406 million and unrealized losses are $119 million . (d) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $40 million as of October 1, 2017 ; and foreign currency forward-exchange contracts with fair values of $162 million as of December 31, 2016 . (e) The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 1, 2017 or December 31, 2016 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our priv ate equity securities carried at cost are based on Level 3 inputs. (f) Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $60 million as of October 1, 2017 ; and foreign currency swaps with fair values of $269 million and foreign currency forward-exchange contracts with fair values of $113 million as of December 31, 2016 . (g) The fair value of our long-term debt (not including the current portion of long-term debt) was $39.0 billion as of October 1, 2017 and $34.9 billion as of December 31, 2016 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of $4.7 billion as of October 1, 2017
Selected Financial Assets and Liabilities Presented in the Condensed Consolidated Balance Sheets	The following table provides the classification of these selected financial assets and liabilities in our condensed consolidated balance sheets: (MILLIONS OF DOLLARS) October 1, December 31, Assets Cash and cash equivalents $ 526 $ 547 Short-term investments 14,146 15,255 Other current assets (a) 288 567 Long-term investments 7,311 7,116 Other noncurrent assets (b) 543 689 $ 22,815 $ 24,175 Liabilities Short-term borrowings, including current portion of long-term debt $ 9,448 $ 10,688 Other current liabilities (c) 277 443 Long-term debt 34,503 31,398 Other noncurrent liabilities (d) 896 1,222 $ 45,124 $ 43,750 (a) As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $97 million ), foreign currency swaps ( $86 million ) and foreign currency forward-exchange contracts ( $105 million ) and, as of December 31, 2016 , include interest rate swaps ( $26 million ), foreign currency swaps ( $43 million ) and foreign currency forward-exchange contracts ( $497 million ). (b) As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $532 million ), foreign currency swaps ( $6 million ) and foreign currency forward-exchange contracts ( $5 million ) and, as of December 31, 2016 , include interest rate swaps ( $599 million ), foreign currency swaps ( $36 million ) and foreign currency forward-exchange contracts ( $54 million ). (c) As of October 1, 2017 , derivative instruments at fair value include foreign currency forward-exchange contracts ( $276 million ) and interest rate swaps ( $1 million ) and, as of December 31, 2016 , include interest rate swaps ( $1 million ), foreign currency swaps ( $300 million ) and foreign currency forward-exchange contracts ( $143 million ). (d) As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $153 million ), foreign currency swaps ( $710 million ) and foreign currency forward-exchange contracts ( $33 million ) and, as of December 31, 2016 , include interest rate swaps ( $147 million ) and foreign currency swaps ( $1.1 billion ).
Contractual Maturities of Available-for-sale and Held-to-maturity Debt Securities	The following table provides the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities: Years October 1, (MILLIONS OF DOLLARS) Within 1 Over 1 to 5 Over 5 to 10 Over 10 Total Available-for-sale debt securities Corporate debt (a) $ 2,741 $ 2,591 $ 1,525 $ 17 $ 6,874 Western European, Asian, and other government debt (b) 6,071 268 — — 6,339 Western European, Scandinavian and other government agency debt (b) 1,955 42 — — 1,998 Supranational debt (b) 387 195 — — 582 Government National Mortgage Association and other U.S. government guaranteed asset-backed securities 42 424 — — 466 Other asset-backed debt (c) 161 61 3 — 226 U.S. government debt — 112 — — 112 Held-to-maturity debt securities Time deposits and other 1,133 — 3 — 1,137 Western European government debt (b) 326 — — — 326 Total debt securities $ 12,818 $ 3,694 $ 1,532 $ 18 $ 18,061 (a) Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade. (b) Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality. (c) Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.
Schedule of Principal Amounts and Components of Unsecured Long-term Debt Issued	The following table provides the amounts of senior unsecured long-term debt issued in the first quarter of 2017: Principal As of October 1, 2017 (MILLIONS) Maturity Date Euro U.S. Dollar 3-month EURIBOR + 0.20% floating rate notes (0% floor) March 6, 2019 € 1,250 $ 1,479 0.00% euro notes (a) March 6, 2020 1,000 1,183 0.25% euro notes (a) March 6, 2022 1,000 1,183 1.00% euro notes (a) March 6, 2027 750 887 Total euro long-term debt issued in the first quarter of 2017 (b) € 4,000 $ 4,732 4.20% notes (c) March 17, 2047 1,065 Total long-term debt issued in the first quarter of 2017 (d) $ 5,797 (a) Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus 0.15% ; plus, in each case, accrued and unpaid interest. The fixed rate euro notes are also redeemable at our option, in whole, or in part, within 30 to 90 days of maturity date. (b) The weighted-average effective interest rate for the euro notes at issuance was 0.23% . (c) The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020. (d) The aggregate amount at issuance date was $5,279 million
Maturity Schedule of Long-term Debt Outstanding	The following table provides the maturity schedule of our Long-term debt outstanding as of October 1, 2017: (MILLIONS OF DOLLARS) 2018 2019 2020 2021 After 2021 Total Maturities $ 481 $ 4,825 $ 1,534 $ 4,502 $ 23,162 $ 34,503
Information about Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk	The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk: Three Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, October 1, October 2, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ 218 $ 87 $ 148 $ (39 ) Foreign currency forward-exchange contracts 1 2 (269 ) (212 ) (204 ) (111 ) Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts — — — — — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts 33 20 — — — — Foreign currency swaps — (4 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency long-term debt — — (166 ) — — — All other net — — 1 — — — $ 34 $ 18 $ (216 ) $ (126 ) $ (55 ) $ (150 ) Nine Months Ended Amount of Gains/(Losses) Recognized in OID (a), (b), (c) Amount of Gains/(Losses) Recognized in OCI (Effective Portion) (a), (d) Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion) (a), (d) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, October 1, October 2, Derivative Financial Instruments in Cash Flow Hedge Relationships: Foreign currency swaps $ — $ — $ 455 $ (204 ) $ 419 $ (165 ) Foreign currency forward-exchange contracts (5 ) 1 (604 ) (770 ) (26 ) (118 ) Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency forward-exchange contracts — 1 — (15 ) — — Derivative Financial Instruments Not Designated as Hedges: Foreign currency forward-exchange contracts (111 ) (49 ) — — — — Foreign currency swaps (1 ) (9 ) — — — — Non-Derivative Financial Instruments in Net Investment Hedge Relationships: Foreign currency short-term borrowings — — — (26 ) — — Foreign currency long-term debt — — (518 ) — — — All other net — — 1 1 — — $ (117 ) $ (56 ) $ (666 ) $ (1,014 ) $ 394 $ (283 ) (a) OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income. COS = Cost of sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income . (b) Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships. (c) There was no significant ineffectiveness for any period presented. (d) For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income––Unrealized holding losses on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net.

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Oct. 01, 2017
Inventory Disclosure [Abstract]
Schedule of Components of Inventories, Current	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) October 1, December 31, Finished goods $ 2,977 $ 2,293 Work-in-process 4,070 3,696 Raw materials and supplies 879 793 Inventories (a) $ 7,925 $ 6,783 Noncurrent inventories not included above (b) $ 669 $ 683 (a) The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand. (b) Included in Other noncurrent assets
Schedule of Components of Inventories, Noncurrent	The following table provides the components of Inventories : (MILLIONS OF DOLLARS) October 1, December 31, Finished goods $ 2,977 $ 2,293 Work-in-process 4,070 3,696 Raw materials and supplies 879 793 Inventories (a) $ 7,925 $ 6,783 Noncurrent inventories not included above (b) $ 669 $ 683 (a) The change from December 31, 2016 reflects the build of inventory primarily for and in advance of new or potential product launches and increases to meet targeted levels for certain products in the normal course of business, including those related to demand. (b) Included in Other noncurrent assets

Identifiable Intangible Asset29

Identifiable Intangible Assets and Goodwill (Tables)	9 Months Ended
	Oct. 01, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : October 1, 2017 December 31, 2016 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,585 $ (53,960 ) $ 35,625 $ 83,390 $ (49,650 ) $ 33,740 Brands 2,135 (1,127 ) 1,008 2,092 (1,032 ) 1,060 Licensing agreements and other 1,930 (1,071 ) 859 1,869 (1,005 ) 864 93,650 (56,158 ) 37,492 87,351 (51,687 ) 35,664 Indefinite-lived intangible assets Brands and other 6,937 6,937 6,883 6,883 IPR&D (a) 5,292 5,292 10,101 10,101 12,229 12,229 16,984 16,984 Identifiable intangible assets (b) $ 105,879 $ (56,158 ) $ 49,721 $ 104,335 $ (51,687 ) $ 52,648 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A ) and (v) impairments of Developed technology rights (see Note 4) . (b) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A ), as well as impairments of Developed technology rights (see Note 4) , partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E
Schedule of Indefinite Lived Intangible Assets	The following table provides the components of Identifiable intangible assets : October 1, 2017 December 31, 2016 (MILLIONS OF DOLLARS) Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Gross Carrying Amount Accumulated Amortization Identifiable Intangible Assets, less Accumulated Amortization Finite-lived intangible assets Developed technology rights (a) $ 89,585 $ (53,960 ) $ 35,625 $ 83,390 $ (49,650 ) $ 33,740 Brands 2,135 (1,127 ) 1,008 2,092 (1,032 ) 1,060 Licensing agreements and other 1,930 (1,071 ) 859 1,869 (1,005 ) 864 93,650 (56,158 ) 37,492 87,351 (51,687 ) 35,664 Indefinite-lived intangible assets Brands and other 6,937 6,937 6,883 6,883 IPR&D (a) 5,292 5,292 10,101 10,101 12,229 12,229 16,984 16,984 Identifiable intangible assets (b) $ 105,879 $ (56,158 ) $ 49,721 $ 104,335 $ (51,687 ) $ 52,648 (a) The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A ) and (v) impairments of Developed technology rights (see Note 4) . (b) The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A ), as well as impairments of Developed technology rights (see Note 4) , partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E
Identifiable Intangible Assets as a Percentage of Total Identifiable Intangible Assets Less Accumulated Amortization, By Segment	Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization: October 1, 2017 IH EH WRD Developed technology rights 68 % 32 % — % Brands, finite-lived 75 % 25 % — % Brands, indefinite-lived 71 % 29 % — % IPR&D 80 % 13 % 7 %
Schedule of Goodwill	The following table provides the components of and changes in the carrying amount of Goodwill : (MILLIONS OF DOLLARS) IH EH Total Balance, December 31, 2016 $ 30,134 $ 24,315 $ 54,449 Additions (a) 572 92 664 Other (b) 491 475 966 Balance, October 1, 2017 $ 31,197 $ 24,882 $ 56,078 (a) IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see Note 2A ). (b)

Pension and Postretirement Be30

Pension and Postretirement Benefit Plans (Tables)	9 Months Ended
	Oct. 01, 2017
Retirement Benefits [Abstract]
Schedule of Net Periodic Benefit Costs	The following table provides the components of net periodic benefit cost/(income): Three Months Ended Pension Plans U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Net periodic benefit cost/(credit): Service cost $ 67 $ 69 $ 6 $ 5 $ 44 $ 41 $ 10 $ 11 Interest cost 157 218 13 18 52 58 23 33 Expected return on plan assets (248 ) (239 ) — — (87 ) (95 ) (9 ) (8 ) Amortization of: Actuarial losses 91 99 12 9 29 23 8 9 Prior service costs (credits) — 1 — — (1 ) (1 ) (45 ) (45 ) Curtailments 1 2 — 1 (2 ) — (3 ) (8 ) Settlements 30 21 7 7 — 1 — — $ 99 $ 170 $ 39 $ 39 $ 35 $ 27 $ (17 ) $ (9 ) Nine Months Ended Pension Plans U.S. Qualified (a) U.S. Supplemental (Non-Qualified) International Postretirement Plans (MILLIONS OF DOLLARS) Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Oct 1, 2017 Oct 2, 2016 Net periodic benefit cost/(credit): Service cost $ 202 $ 193 $ 18 $ 14 $ 127 $ 126 $ 32 $ 31 Interest cost 478 486 41 40 152 178 68 77 Expected return on plan assets (759 ) (721 ) — — (256 ) (291 ) (27 ) (25 ) Amortization of: Actuarial losses 302 297 37 27 86 70 23 23 Prior service costs (credits) 3 4 (1 ) (1 ) (3 ) (2 ) (137 ) (127 ) Curtailments 10 5 — 1 (2 ) (1 ) (15 ) (14 ) Settlements 54 52 32 23 3 2 — — $ 292 $ 316 $ 127 $ 105 $ 106 $ 81 $ (57 ) $ (36 ) (a) In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3
Schedule of Employer Contributions to Pension and Postretirement Plans	As of and for the nine months ended October 1, 2017 , we contributed and expect to contribute in 2017 from our general assets as follows: Pension Plans (MILLIONS OF DOLLARS) U.S. Qualified U.S. Supplemental (Non-Qualified) International Postretirement Plans Contributions from our general assets for the nine months ended October 1, 2017 $ 1,095 $ 121 $ 134 $ 158 Expected contributions from our general assets during 2017 (a) $ 1,095 $ 146 $ 170 $ 204 (a) Contributions expected to be made for 2017 are inclusive of amounts contributed during the nine months ended October 1, 2017 , including the $1.0 billion

Earnings Per Common Share Att31

Earnings Per Common Share Attributable to Common Shareholders (Tables)	9 Months Ended
	Oct. 01, 2017
Earnings Per Share [Abstract]
Schedule of Basic and Diluted Earning Per Share	The following table provides the detailed calculation of Earnings per common share (EPS) : Three Months Ended Nine Months Ended (IN MILLIONS) October 1, October 2, October 1, October 2, EPS Numerator––Basic Income from continuing operations (a) $ 2,858 $ 1,355 $ 9,064 $ 6,465 Less: Net income attributable to noncontrolling interests 18 — 32 25 Income from continuing operations attributable to Pfizer Inc. (a) 2,840 1,355 9,032 6,440 Less: Preferred stock dividends––net of tax — — 1 1 Income from continuing operations attributable to Pfizer Inc. common shareholders (a) 2,839 1,355 9,032 6,439 Discontinued operations––net of tax — — 1 — Net income attributable to Pfizer Inc. common shareholders (a) $ 2,839 $ 1,355 $ 9,033 $ 6,439 EPS Numerator––Diluted Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions (a) $ 2,840 $ 1,355 $ 9,032 $ 6,440 Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions — — 1 — Net income attributable to Pfizer Inc. common shareholders and assumed conversions (a) $ 2,840 $ 1,355 $ 9,034 $ 6,440 EPS Denominator Weighted-average number of common shares outstanding––Basic 5,951 6,066 5,972 6,095 Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (a) 89 84 85 80 Weighted-average number of common shares outstanding––Diluted (a) 6,041 6,150 6,057 6,175 Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (a), (b) 47 38 47 60 (a) Amounts for the third quarter and first nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016 , as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B ). (b)

Segment, Geographic and Other32

Segment, Geographic and Other Revenue Information (Tables)	9 Months Ended
	Oct. 01, 2017
Segment Reporting [Abstract]
Reconciliation of Revenue from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Reportable Segments: IH $ 8,118 $ 7,332 $ 4,875 $ 4,187 EH 5,050 5,712 2,765 3,128 Total reportable segments 13,168 13,045 7,640 7,315 Other business activities (b), (c) — — (759 ) (753 ) Reconciling Items: Corporate (c) — — (1,382 ) (1,537 ) Purchase accounting adjustments (c) — — (1,154 ) (966 ) Acquisition-related costs (c) — — (155 ) (280 ) Certain significant items (d) — — (449 ) (1,969 ) Other unallocated — — (156 ) (206 ) $ 13,168 $ 13,045 $ 3,585 $ 1,604 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Reportable Segments: IH $ 23,204 $ 21,471 $ 14,190 $ 12,470 EH 15,639 17,725 8,558 9,985 Total reportable segments 38,843 39,196 22,748 22,454 Other business activities (b), (c) — — (2,205 ) (2,096 ) Reconciling Items: Corporate (c) — — (3,948 ) (4,217 ) Purchase accounting adjustments (c) — — (3,527 ) (3,103 ) Acquisition-related costs (c) — — (347 ) (598 ) Certain significant items (d) — — (797 ) (4,112 ) Other unallocated — — (573 ) (753 ) $ 38,843 $ 39,196 $ 11,351 $ 7,575 (a) Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million , respectively, from our investment in ViiV. For additional information, see Note 4. (b) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $33 million and $94 million of costs from Other Business Activities to Corporate in the third quarter and first nine months of 2016 , respectively, to conform to the current period presentation. (c) For a description, see the “Other Costs and Business Activities” section above. (d) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $90 million , (ii) charges for certain legal matters of $183 million , (iii) income of $12 million , representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $45 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $253 million , (ii) charges for certain legal matters of $191 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $52 million , (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $54 million and (vi) other charges of $119 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 3 and Note 4
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	The following table provides selected income statement information by reportable segment: Three Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Reportable Segments: IH $ 8,118 $ 7,332 $ 4,875 $ 4,187 EH 5,050 5,712 2,765 3,128 Total reportable segments 13,168 13,045 7,640 7,315 Other business activities (b), (c) — — (759 ) (753 ) Reconciling Items: Corporate (c) — — (1,382 ) (1,537 ) Purchase accounting adjustments (c) — — (1,154 ) (966 ) Acquisition-related costs (c) — — (155 ) (280 ) Certain significant items (d) — — (449 ) (1,969 ) Other unallocated — — (156 ) (206 ) $ 13,168 $ 13,045 $ 3,585 $ 1,604 Nine Months Ended Revenues Earnings (a) (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Reportable Segments: IH $ 23,204 $ 21,471 $ 14,190 $ 12,470 EH 15,639 17,725 8,558 9,985 Total reportable segments 38,843 39,196 22,748 22,454 Other business activities (b), (c) — — (2,205 ) (2,096 ) Reconciling Items: Corporate (c) — — (3,948 ) (4,217 ) Purchase accounting adjustments (c) — — (3,527 ) (3,103 ) Acquisition-related costs (c) — — (347 ) (598 ) Certain significant items (d) — — (797 ) (4,112 ) Other unallocated — — (573 ) (753 ) $ 38,843 $ 39,196 $ 11,351 $ 7,575 (a) Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million , respectively, from our investment in ViiV. For additional information, see Note 4. (b) Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $33 million and $94 million of costs from Other Business Activities to Corporate in the third quarter and first nine months of 2016 , respectively, to conform to the current period presentation. (c) For a description, see the “Other Costs and Business Activities” section above. (d) Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $90 million , (ii) charges for certain legal matters of $183 million , (iii) income of $12 million , representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $45 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $253 million , (ii) charges for certain legal matters of $191 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $52 million , (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $54 million and (vi) other charges of $119 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 3 and Note 4
Schedule of Revenues by Geographic Region	The following table provides revenues by geographic area: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, % Change October 1, October 2, % Change U.S. $ 6,534 $ 6,530 — $ 19,516 $ 19,561 — Developed Europe (a) 2,163 2,218 (2 ) 6,309 6,982 (10 ) Developed Rest of World (b) 1,632 1,711 (5 ) 4,797 4,940 (3 ) Emerging Markets (c) 2,839 2,586 10 8,222 7,714 7 Revenues $ 13,168 $ 13,045 1 $ 38,843 $ 39,196 (1 ) (a) Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the third quarter of 2017 and 2016 , and $5.0 billion and $5.3 billion in the first nine months of 2017 and 2016 , respectively. (b) Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand. (c) Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.
Schedule of Significant Product Revenues	The following table provides detailed revenue information: Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, PFIZER INNOVATIVE HEALTH (IH) (a) $ 8,118 $ 7,332 $ 23,204 $ 21,471 Internal Medicine $ 2,455 $ 2,243 $ 7,245 $ 6,557 Lyrica IH (b) 1,150 1,049 3,382 3,107 Eliquis alliance revenues and direct sales 644 449 1,813 1,225 Chantix/Champix 240 198 727 631 Viagra IH (c) 206 297 711 897 BMP2 79 63 198 175 Toviaz 62 60 187 191 All other Internal Medicine 75 128 228 330 Vaccines $ 1,649 $ 1,641 $ 4,385 $ 4,576 Prevnar 13/Prevenar 13 1,522 1,536 4,069 4,302 FSME/IMMUN-TicoVac 43 33 119 102 All other Vaccines 85 72 197 172 Oncology $ 1,616 $ 1,104 $ 4,551 $ 3,206 Ibrance 878 550 2,410 1,492 Sutent 276 260 805 823 Xalkori 146 140 442 415 Xtandi alliance revenues 150 2 422 2 Inlyta 84 95 256 304 Bosulif 57 43 163 121 All other Oncology 26 15 54 49 Inflammation & Immunology (I&I) $ 1,000 $ 960 $ 2,863 $ 2,907 Enbrel (Outside the U.S. and Canada) 613 701 1,818 2,201 Xeljanz 348 235 935 649 Eucrisa 15 — 33 — All other I&I 23 24 78 57 Rare Disease $ 569 $ 585 $ 1,637 $ 1,768 BeneFIX 151 176 453 543 Refacto AF/Xyntha 140 140 409 408 Genotropin 136 147 375 425 Somavert 65 59 182 173 All other Rare Disease 77 64 218 219 Consumer Healthcare $ 829 $ 798 $ 2,522 $ 2,457 PFIZER ESSENTIAL HEALTH (EH) (d) $ 5,050 $ 5,712 $ 15,639 $ 17,725 Legacy Established Products (LEP) (e) $ 2,681 $ 2,708 $ 7,995 $ 8,373 Lipitor 491 422 1,341 1,294 Premarin family 238 244 711 751 Norvasc 226 238 684 714 EpiPen 82 110 253 300 Xalatan/Xalacom 83 91 241 273 Effexor 76 70 215 207 Zoloft 78 72 215 228 Zithromax 61 56 202 203 Relpax 50 83 193 248 Xanax 58 55 164 163 All other LEP 1,237 1,268 3,776 3,992 Sterile Injectable Pharmaceuticals (SIP) (f) $ 1,273 $ 1,461 $ 4,270 $ 4,481 Medrol 109 102 352 330 Sulperazon 114 102 345 304 Fragmin 79 80 221 240 Tygacil 60 69 192 203 Precedex 51 64 182 199 All other SIP 860 1,044 2,977 3,206 Three Months Ended Nine Months Ended (MILLIONS OF DOLLARS) October 1, October 2, October 1, October 2, Peri-LOE Products (g) $ 794 $ 1,023 $ 2,398 $ 3,224 Celebrex 212 194 564 550 Lyrica EH (b) 134 191 428 623 Vfend 97 140 305 459 Viagra EH (c) 102 89 285 286 Pristiq 69 174 230 546 Zyvox 68 94 220 334 Revatio 58 73 189 213 All other Peri-LOE Products 55 68 176 214 Biosimilars (h) $ 141 $ 83 $ 367 $ 228 Inflectra/Remsima 112 49 284 130 All other Biosimilars 28 34 82 97 Pfizer CentreOne (i) $ 161 $ 156 $ 514 $ 540 Hospira Infusion Systems (HIS) (j) $ — $ 281 $ 97 $ 879 Revenues $ 13,168 $ 13,045 $ 38,843 $ 39,196 Total Lyrica (b) $ 1,285 $ 1,240 $ 3,810 $ 3,730 Total Viagra (c) $ 308 $ 387 $ 996 $ 1,183 Total Alliance revenues $ 741 $ 419 $ 2,112 $ 1,155 (a) The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH. (b) Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH. (c) Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH. (d) The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations. (e) Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH. See note (a) above. (f) Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products). (g) Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra. (h) Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets. (i) Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis. (j) HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.

Basis of Presentation and Sig33

Basis of Presentation and Significant Accounting Policies (Details) $ / shares in Units, $ in Millions		3 Months Ended	9 Months Ended
		Oct. 02, 2016USD ($)	Oct. 01, 2017USD ($)Operating_Segment	Oct. 02, 2016USD ($)	Sep. 28, 2016$ / shares	Jun. 24, 2016$ / shares
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of business segments | Operating_Segment			2
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Net tax benefit		$ 35		$ 85
Amount reclassified from operating activities	[1],[2]		$ (9,728)	(10,151)
Amount reclassified to financing activities	[1],[2]		$ (9,650)	(6,915)
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares					$ 81.50
Anacor [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share) | $ / shares						$ 99.25
Accounting Standards Update 2016-09, Statutory Tax Withholding Component [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Amount reclassified from operating activities				87
Amount reclassified to financing activities				$ 87
[1]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira34

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - AstraZeneca (Details) - USD ($) $ in Millions		Dec. 22, 2016	Apr. 01, 2018	Jul. 02, 2017	Oct. 01, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	[1]				$ 56,078	$ 54,449
AstraZeneca [Member]
Business Acquisition [Line Items]
Initial payment		$ 552
Additional payment made for a purchase price adjustment				$ 3
Milestone payment				$ 50
Deferred payment		175
Maximum amount of potential milestone payments		75
Maximum amount of potential sales-related payments		$ 600
Term of royalty payments		10 years
Consideration transferred in business acquisition		$ 1,045
Payments for acquisitions, cash portion		555
Contingent consideration assumed		490
Identifiable intangible assets		879
Other current assets		92
Goodwill		92
Deferred tax liabilities		17
In Process Research and Development [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		219
Developed Technology Rights [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		660
Minimum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Undiscounted royalty payments		250
Maximum [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Undiscounted royalty payments		$ 425
Forecast [Member] | AstraZeneca [Member]
Business Acquisition [Line Items]
Milestone payment			$ 125
[1]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira35

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Medivation (Details) - USD ($) $ / shares in Units, $ in Millions		Sep. 28, 2016	Oct. 01, 2017	Oct. 01, 2017	Oct. 01, 2017	Dec. 31, 2016
Business Acquisition [Line Items]
Goodwill	[1]		$ 56,078	$ 56,078	$ 56,078	$ 54,449
Medivation [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 81.50
Consideration transferred in business acquisition		$ 14,300
Consideration transferred in business acquisition, net of cash acquired		13,900
Amount payable						$ 365
Identifiable intangible assets		12,200
Goodwill		6,100
Deferred tax liabilities		4,000
Contingent consideration assumed		259
Reduction in intangible assets due to measurement period adjustments					$ 1,000
Decrease in amortization of intangible assets due to measurement period adjustments			$ 38	$ 38
Medivation [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		4,100
Medivation [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 8,100
Acquired intangible assets, average useful life		12 years
[1]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira36

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Bamboo Therapeutics (Details) - USD ($) $ in Millions		Aug. 01, 2016	Oct. 02, 2016	Apr. 03, 2016	Oct. 01, 2017	Oct. 02, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]				$ 1,000	$ 17,679
Goodwill	[2]				$ 56,078		$ 54,449
Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Payment to acquire the remaining equity		$ 150
Maximum amount of potential milestone payments		495
Total fair value of consideration transferred		343
Payments for acquisitions, cash portion		130		$ 43
Cash payments for acquisition, net of cash acquired		101
Contingent consideration incurred		167
Fair value of previously held equity interest		45
Goodwill		142
Deferred tax liabilities		94
Other (Income)/Deductions, Net [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Gain recognized upon acquisition of remaining interest in acquiree			$ 2
In Process Research and Development [Member] | Bamboo Therapeutics [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 330
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira37

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Anacor Pharmaceuticals, Inc. (Details) - USD ($) $ / shares in Units, $ in Millions		Jun. 24, 2016	Oct. 01, 2017	Oct. 02, 2016	Dec. 31, 2016
Business Acquisition [Line Items]
Cash payments for acquisition, net of cash acquired	[1]		$ 1,000	$ 17,679
Goodwill	[2]		$ 56,078		$ 54,449
Anacor [Member]
Business Acquisition [Line Items]
Business acquisition, per share in cash (in dollars per share)		$ 99.25
Payments for acquisitions, cash portion		$ 4,900
Cash payments for acquisition, net of cash acquired		4,500
Debt assumed		698
IPR&D		4,900
Goodwill		646
Deferred tax liabilities		346
Anacor [Member] | In Process Research and Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets		$ 4,800
[1]	Amounts may not add due to rounding.
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira38

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc. (EH) (Details) - USD ($) shares in Millions, $ in Millions		Feb. 03, 2017	Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016	[2]	Jan. 05, 2017	Oct. 06, 2016
Business Acquisition [Line Items]
Gain (loss) on sale of HIS net assets	[1]		$ 12	$ (1,422)	$ (52)	[2]	$ (1,422)
HIS [Member] | Disposed of by Sale [Member] | ICU Medical [Member]
Business Acquisition [Line Items]
Consideration transferred									$ 900	$ 1,000
Number of shares received in disposition		3.2
Value of shares received from disposition		$ 428
Promissory note		75
Cash received from disposition		200
Contingent consideration		$ 225
Ownership percentage			16.00%		16.00%
Minimum share transfer restriction term		18 months
Term of promissory note		3 years
Gain (loss) on sale of HIS net assets			$ 12		$ (52)
Administrative service period		24 months
Maximum manufacturing service period		5 years
London Interbank Offered Rate (LIBOR) [Member] | HIS [Member] | Disposed of by Sale [Member] | ICU Medical [Member]
Business Acquisition [Line Items]
Interest rate of promissory note in year one		2.25%
Interest rate of promissory note in year two		2.50%
Interest rate of promissory note in year three		2.50%
[1]	In the third quarter and first nine months of 2017 , represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.
[2]	Amounts may not add due to rounding.

Acquisitions, Sale of Hospira39

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Collaboration Arrangement (Details) - Other (Income)/Deductions, Net [Member] - Merck KGaA [Member] - Collaborative Arrangement [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Apr. 02, 2017	Oct. 01, 2017
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Upfront payments received	$ 90
Collaborator's revenue and expense ownership percentage		60.00%
Company's revenue and expense ownership percentage		40.00%

Acquisitions, Sale of Hospira40

Acquisitions, Sale of Hospira Infusion Systems Net Assets, Collaborative Arrangement and Equity-Method Investments - Equity-Method Investments (Details) - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2017	Oct. 02, 2016	Jun. 30, 2017
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		49.00%
Equity method investment, impairment		$ 211
Equity method investments	$ 270
Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, ownership percentage		40.00%	40.00%
Equity method investment, impairment		$ 50
Loss on disposal of equity method investment	$ 30
Laboratorio Teuto Brasilero [Member] | Other (Income)/Deductions, Net [Member]
Schedule of Equity Method Investments [Line Items]
Equity method investment, impairment		$ 50
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]
Schedule of Equity Method Investments [Line Items]
Ownership percentage			60.00%

Restructuring Charges and Oth41

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($) $ in Millions		Sep. 03, 2015	Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016	Dec. 31, 2015	Sep. 03, 2018
Restructuring Cost and Reserve [Line Items]
Integration costs	[1]		$ 73	$ 74	$ 224	$ 300
Restructuring charges:
Employee terminations	[2]		(20)	347	9	464
Asset impairments	[2],[3]		101	27	126	45
Exit costs	[2]		10	29	16	64
Total restructuring charges	[2]		91	404	150	574
Transaction costs	[4]		(14)	54	4	114
Integration costs	[1]		73	74	224	300
Restructuring charges and certain acquisition-related costs	[5]		149	531	377	988
Total additional depreciation––asset restructuring	[6]		39	47	74	151
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[7]		57	78	150	202
Total costs associated with acquisitions and cost-reduction/productivity initiatives			245	655	601	1,341
Cost of Sales [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[6]		39	46	74	145
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[7]		26	46	77	127
Selling, Informational and Administrative Expenses [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[7]		22	23	46	56
Research and Development Expense [Member]
Restructuring charges:
Total additional depreciation––asset restructuring	[6]		0	1	0	5
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[7]		9	8	26	17
Other (Income)/Deductions - Net [Member]
Implementation costs recorded in our condensed consolidated statements of income as follows:
Total implementation costs	[7]		0	$ 1	0	$ 2
Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred associated with the return of acquired in-process research and development rights					253
Expected restructuring cost			1,000		$ 1,000
Percentage of expected costs to be non-cash					20.00%
Manufacturing Plant Network Optimization [Member] | Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			800		$ 800
Restructuring costs incurred			122		122
Centralization of Corporate and Platform Functions [Member] | Enterprise-wide Cost Reduction/Productivity Plan [Member]
Restructuring Cost and Reserve [Line Items]
Expected restructuring cost			200		200
Restructuring costs incurred			$ 131		131
Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred associated with the return of acquired in-process research and development rights					110
Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Expected integration related costs, period		3 years
Hospira [Member] | Return of Acquired Rights [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred associated with the return of acquired in-process research and development rights							$ 215
Hospira [Member] | Business Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring cost incurred associated with the return of acquired in-process research and development rights					$ 238
Forecast [Member] | Hospira [Member]
Restructuring Cost and Reserve [Line Items]
Integration costs								$ 1,000
Restructuring charges:
Integration costs								$ 1,000
[1]	Integration costs represent external, incremental costs directly related to integrating acquired businesses, and primarily include expenditures for consulting and the integration of systems and processes. In the third quarter and first nine months of 2017 , integration costs primarily relate to our acquisitions of Hospira and Medivation. The first nine months of 2017 also include a net gain of $12 million related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see Note 10 ). In the third quarter of 2016 , integration costs were mostly related to our acquisition of Hospira, and in the first nine months of 2016
[2]	In the third quarter and first nine months of 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the third quarter and first nine months of 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first nine months ended October 1, 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities for 2017 are associated with the following: • For the third quarter of 2017 , IH ( $4 million ); EH ( $1 million ); WRD/GPD ( $15 million ); manufacturing operations ( $47 million ); and Corporate ( $25 million ). • For the first nine months of 2017 , IH ( $10 million ); EH ( $9 million income); WRD/GPD ( $29 million ); manufacturing operations ( $70 million ); and Corporate ( $51 million ). The restructuring activities for 2016 are associated with the following: • For the third quarter of 2016 , IH ( $148 million ); EH ( $28 million ); WRD/GPD ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million
[3]	The asset impairment charges for the third quarter and the first nine months of 2017
[4]	Transaction costs represent external costs for banking, legal, accounting and other similar services, which in the third quarter of 2017 reflect the reversal of an accrual related to the acquisition of Medivation. Transaction costs for the first nine months of 2017 are directly related to our acquisitions of Hospira, Anacor and Medivation. Transaction costs in the third quarter of 2016 were mostly related to the Medivation acquisition, and in the first nine months of 2016
[5]	Amounts may not add due to rounding.
[6]	Additional depreciation––asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[7]	Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

Restructuring Charges and Oth42

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Footnotes (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016
Restructuring Cost and Reserve [Line Items]
Provision	[1]	$ 91	$ 404	$ 150		$ 574
Corporate [Member]
Restructuring Cost and Reserve [Line Items]
Provision		25	67	51		107
IH [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Provision		4	148	10		162
EH [Member] | Operating Segments [Member]
Restructuring Cost and Reserve [Line Items]
Provision		1	28	(9)		19
WRD & GPD [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Provision		15	52	29		104
Manufacturing operations [Member] | Segment Reconciling Items [Member]
Restructuring Cost and Reserve [Line Items]
Provision		47	108	70		181
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Restructuring Cost and Reserve [Line Items]
Net gain related to the settlement		$ (30)	$ (21)	(54)	[2]	$ (52)	[2]
Hospira [Member] | Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Restructuring Cost and Reserve [Line Items]
Net gain related to the settlement				$ 12
[1]	In the third quarter and first nine months of 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the third quarter and first nine months of 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first nine months ended October 1, 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities for 2017 are associated with the following: • For the third quarter of 2017 , IH ( $4 million ); EH ( $1 million ); WRD/GPD ( $15 million ); manufacturing operations ( $47 million ); and Corporate ( $25 million ). • For the first nine months of 2017 , IH ( $10 million ); EH ( $9 million income); WRD/GPD ( $29 million ); manufacturing operations ( $70 million ); and Corporate ( $51 million ). The restructuring activities for 2016 are associated with the following: • For the third quarter of 2016 , IH ( $148 million ); EH ( $28 million ); WRD/GPD ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million
[2]	In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3

Restructuring Charges and Oth43

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			$ 1,583
Provision	[2]	$ 91	$ 404	150	$ 574
Utilization and other	[3]			(551)
Balance, October 1, 2017	[4]	1,182		1,182
Employee Termination Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			1,547
Provision				9
Utilization and other	[3]			(401)
Balance, October 1, 2017	[4]	1,154		1,154
Asset Impairment Charges [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			0
Provision				126
Utilization and other	[3]			(126)
Balance, October 1, 2017	[4]	0		0
Exit Costs [Member]
Restructuring Reserve [Roll Forward]
Balance, December 31, 2016	[1]			36
Provision				16
Utilization and other	[3]			(24)
Balance, October 1, 2017	[4]	$ 28		$ 28
[1]	Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million
[2]	In the third quarter and first nine months of 2017 , restructuring charges are primarily associated with our acquisitions of Hospira and Medivation, as well as cost-reduction and productivity initiatives not associated with acquisitions. In the third quarter and first nine months of 2016 , restructuring charges are largely associated with cost-reduction and productivity initiatives not associated with acquisitions, as well as our acquisitions of Hospira and Medivation. In the third quarter and first nine months ended October 1, 2017 , Employee terminations primarily include revisions of our estimates of severance benefits. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination. The restructuring activities for 2017 are associated with the following: • For the third quarter of 2017 , IH ( $4 million ); EH ( $1 million ); WRD/GPD ( $15 million ); manufacturing operations ( $47 million ); and Corporate ( $25 million ). • For the first nine months of 2017 , IH ( $10 million ); EH ( $9 million income); WRD/GPD ( $29 million ); manufacturing operations ( $70 million ); and Corporate ( $51 million ). The restructuring activities for 2016 are associated with the following: • For the third quarter of 2016 , IH ( $148 million ); EH ( $28 million ); WRD/GPD ( $52 million ); manufacturing operations ( $108 million ); and Corporate ( $67 million ). • For the first nine months of 2016 , IH ( $162 million ); EH ( $19 million ); WRD/GPD ( $104 million ); manufacturing operations ( $181 million ); and Corporate ( $107 million
[3]	Includes adjustments for foreign currency translation.
[4]	Included in Other current liabilities ( $533 million ) and Other noncurrent liabilities ( $650 million

Restructuring Charges and Oth44

Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($) $ in Millions	Oct. 01, 2017		Dec. 31, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 1,182	[1]	$ 1,583	[2]
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	533		863
Other Noncurrent Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring reserve	$ 650		$ 720
[1]	Included in Other current liabilities ( $533 million ) and Other noncurrent liabilities ( $650 million
[2]	Included in Other current liabilities ( $863 million ) and Other noncurrent liabilities ( $720 million

Other (Income)_Deductions - N45

Other (Income)/Deductions - Net (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016
Other Income and Expenses [Abstract]
Interest income	[1]	$ (99)	$ (123)	$ (275)		$ (357)
Interest expense	[1]	320	291	940		889
Net interest expense		220	168	666		532
Royalty-related income	[2]	(140)	(233)	(331)		(695)
Certain legal matters, net	[3]	183	(40)	194		494
Net gains on asset disposals	[4]	(155)	(47)	(349)		(81)
Loss on sale and impairment on remeasurement of HIS net assets	[5]	(12)	1,422	52	[6]	1,422	[6]
Certain asset impairments	[7]	130	133	143		1,080
Business and legal entity alignment costs	[8]	16	69	54		180
Other, net	[9]	(191)	(55)	(445)		(117)
Other (income)/deductions––net	[10]	$ 51	$ 1,417	$ (16)		$ 2,815
[1]	Interest income decreased in the third quarter and first nine months of 2017 , primarily driven by a lower investment balance. Interest expense increased in the third quarter and first nine months of 2017 , primarily as a result of higher short-term interest rates, offset, in part, by the retirement of high-coupon debt and the issuance of new low-coupon debt
[2]	Royalty-related income decreased in the third quarter and first nine months of 2017 , primarily due to lower royalty income for Enbrel of $139 million and $414 million , respectively, resulting from the expiration on October 31, 2016 of the 36 -month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $73 million and $160 million
[3]	In the third quarter and first nine months of 2017 , primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a $79 million charge to reflect damages awarded by a jury in a patent matter. In the first nine months of 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the first nine months of 2016
[4]	In the third quarter of 2017 , primarily includes gains on sales/out-licensing of product and compound rights (approximately $71 million ) and gains on sales and redemptions of investments in equity and debt securities (approximately $66 million ). In the first nine months of 2017 , primarily includes gains on sales and redemptions of investments in equity and debt securities (approximately $183 million ), gains on sales/out-licensing of product and compound rights (approximately $141 million ) and a gain on sale of property (approximately $52 million ), partially offset by a net loss related to the sale of our 40% ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest (approximately $30 million ). In the first nine months of 2016 , includes gains on sales/out-licensing of product and compound rights (approximately $49 million
[5]	In the third quarter and first nine months of 2017 , represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.
[6]	Amounts may not add due to rounding.
[7]	In the third quarter and first nine months of 2017 , primarily includes an intangible asset impairment charge of $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the third quarter and first nine months of 2017 is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the third quarter of 2016 , primarily includes intangible asset impairment charges of $126 million , reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ( $97 million ) and IH ( $29 million ). In the first nine months of 2016 , primarily includes intangible asset impairment charges of $767 million , reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ( $738 million ) and IH ( $29 million ). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer’s 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D.
[8]	In the third quarter and first nine months of 2017 and 2016
[9]	In the third quarter and first nine months of 2017 , includes, among other things, dividend income of $54 million and $211 million , respectively, from our investment in ViiV, and income of $62 million from resolution of a contract disagreement. In the first nine months of 2016 , includes, among other things, $150 million paid to Allergan for reimbursement of Allergan’s expenses associated with the terminated transaction and income of $116 million
[10]	Amounts may not add due to rounding.

Other (Income)_Deductions - N46

Other (Income)/Deductions - Net (Footnotes) (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016	Jun. 30, 2017
Loss Contingencies [Line Items]
Royalty revenue	[1]	$ 140	$ 233	$ 331	$ 695
Gain on sale of investments		66		183
Gain on sale of property				52
Intangible asset impairment charges			$ 126		767
Income from contract resolution		62		62	116
Payments for merger termination costs					$ 150
Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage			40.00%		40.00%	40.00%
Loss on disposal of equity method investment				30
Equity method investment, impairment					$ 50
Hisun Pfizer Pharmaceuticals Co. Ltd [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage			49.00%		49.00%
Equity method investment, impairment					$ 211
Xtandi [Member]
Loss Contingencies [Line Items]
Royalty revenue		73		160
Distribution Rights [Member]
Loss Contingencies [Line Items]
Gain on disposition of intangible assets		71		141	49
Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges					331
Collaborative Arrangement, Co-promotion [Member] | Enbrel [Member]
Loss Contingencies [Line Items]
Decrease in royalty revenue		139		$ 414
Royalty period				36 months
Pending Litigation [Member] | Celebrex [Member]
Loss Contingencies [Line Items]
Litigation settlement expense		94		$ 94
Pending Litigation [Member] | Celebrex and Bextra [Member]
Loss Contingencies [Line Items]
Amount awarded to other party					486
In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges					265
Other In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges					74
Hospira [Member] | Other In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges					45
InnoPharma [Member] | In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges			$ 97		97
King [Member] | Other In Process Research and Development [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges			29		29
Operating Segments [Member] | EH [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges			97		738
Operating Segments [Member] | EH [Member] | Hospira [Member] | Developed Technology Rights [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges		127		127
Operating Segments [Member] | IH [Member]
Loss Contingencies [Line Items]
Intangible asset impairment charges			$ 29		$ 29
Operating Segments [Member] | IH [Member] | ViiV Healthcare Limited [Member]
Loss Contingencies [Line Items]
Dividend income		54		211
Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]
Loss Contingencies [Line Items]
Ownership percentage						60.00%
Patent Matter [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Litigation settlement expense		$ 79		$ 79
[1]	Royalty-related income decreased in the third quarter and first nine months of 2017 , primarily due to lower royalty income for Enbrel of $139 million and $414 million , respectively, resulting from the expiration on October 31, 2016 of the 36 -month royalty period under the collaboration agreement for Enbrel in the U.S. and Canada (the collaboration period under the agreement expired on October 31, 2013), partially offset by the addition of Xtandi royalty-related income of $73 million and $160 million

Other (Income)_Deductions - N47

Other (Income)/Deductions - Net - Impaired Intangible Assets (Detail) - Developed Technology Rights [Member] $ in Millions	9 Months Ended
	Oct. 01, 2017USD ($)	[1]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, fair value disclosure	$ 50	[2]
Impairment of finite-lived intangible assets	127
Level 1 [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, fair value disclosure	0	[2]
Level 2 [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, fair value disclosure	0	[2]
Level 3 [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, fair value disclosure	$ 50	[2]
[1]	Reflects intangible assets written down to fair value in the third quarter of 2017
[2]	The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis.

Tax Matters - Narrative (Detail

Tax Matters - Narrative (Detail)	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Income Tax Disclosure [Abstract]
Effective tax rate for income from continuing operations	20.30%	15.50%	20.10%	14.60%

Tax Matters (Detail)

Tax Matters (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Income Tax Disclosure [Abstract]
Foreign currency translation adjustments, net	[1]	$ (62)	$ 0	$ (192)	$ (15)
Unrealized holding losses on derivative financial instruments, net		28	0	30	(192)
Reclassification adjustments for realized (gains)/losses		(29)	32	(169)	81
Derivatives qualifying as hedges, tax, total		(1)	32	(139)	(112)
Unrealized holding gains on available-for-sale securities, net		37	40	93	106
Reclassification adjustments for realized gains		(49)	(14)	(45)	(16)
Available-for-sale securities, tax, total		(12)	26	47	90
Benefit plans: actuarial losses, net		(37)	(31)	(15)	(39)
Reclassification adjustments related to amortization		60	47	152	140
Reclassification adjustments related to settlements, net		22	10	30	27
Other		(33)	14	(46)	5
Defined benefit plans, actuarial gain (loss), tax, total		11	40	121	133
Benefit plans: prior service (costs)/credits and other, net		0	35	0	66
Reclassification adjustments related to amortization		(17)	(17)	(50)	(47)
Reclassification adjustments related to curtailments, net		(1)	(3)	(5)	(5)
Other		1	2	1	1
Pension and other postretirement benefit plans, net prior service cost (credit), tax		(17)	18	(55)	15
Tax provision/(benefit) on other comprehensive income	[2],[3]	$ (80)	$ 116	$ (218)	$ 111
[1]	Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.
[2]	Amounts may not add due to rounding.
[3]	See Note 5C. Tax Matters: Tax Provision/(Benefit) on Other Comprehensive Income.

Accumulated Other Comprehensi50

Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Detail) $ in Millions	9 Months Ended
	Oct. 01, 2017USD ($)
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	$ 59,544	[1]
Balance, October 1, 2017	60,770	[1]
Foreign currency translation adjustments attributable to noncontrolling interests	16
Accumulated Other Comprehensive Income (Loss) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	(11,036)
Other comprehensive income/(loss)	1,872	[2]
Balance, October 1, 2017	(9,164)
Foreign Currency Translation Adjustment [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	(6,659)
Other comprehensive income/(loss)	1,638	[2]
Balance, October 1, 2017	(5,021)
Derivative Financial Instruments [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	348
Other comprehensive income/(loss)	(403)	[2]
Balance, October 1, 2017	(55)
Cash flow hedge loss to be reclassified within twelve months	154
Available-For-Sale Securities [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	(131)
Other comprehensive income/(loss)	470	[2]
Balance, October 1, 2017	339
Actuarial Gains/(Losses) [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	(5,473)
Other comprehensive income/(loss)	263	[2]
Balance, October 1, 2017	(5,210)
Prior Service (Costs)/Credits and Other [Member]
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Balance, December 31, 2016	879
Other comprehensive income/(loss)	(96)	[2]
Balance, October 1, 2017	$ 783
[1]	Amounts may not add due to rounding.
[2]	Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of $16 million income for the first nine months of 2017

Financial Instruments - Assets

Financial Instruments - Assets and Liabilities Measured on Recurring Basis (Detail) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Other selected financial assets
Total selected financial assets		$ 22,815	$ 24,175
Short-term borrowings:
Total short-term borrowings, carried at historical proceeds, as adjusted	[1],[2]	9,448	10,688
Long-term debt:
Total long-term debt, carried at historical proceeds, as adjusted	[1],[3]	34,503	31,398
Total		43,951	42,085
Total selected financial liabilities		45,124	43,750
Reported Value Measurement [Member]
Other selected financial assets
Held-to-maturity debt securities, carried at amortized cost	[2],[4]	1,464	1,242
Restricted stock and private equity securities, carried at cost or at equity-method	[2]	719	735
Total		2,183	1,977
Long-term debt [Member]
Short-term borrowings:
Net fair value adjustments related to hedging and purchase accounting		981	998
Net unamortized discounts, premiums and debt issuance costs		(149)	(130)
Long-term debt:
Principal amount		33,671	30,529
Short-term Debt [Member]
Short-term borrowings:
Principal amount		9,460	10,674
Net fair value adjustments related to hedging and purchase accounting		2	24
Net unamortized discounts, premiums and debt issuance costs		(15)	(11)
Fair Value, Measurements, Recurring [Member]
Assets, Fair Value Disclosure [Abstract]
Trading funds and securities	[5],[6]	347	325
Selected financial assets measured at fair value on a recurring basis	[6],[7]	20,631	22,198
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[6],[8]	1,173	1,665
Fair Value, Measurements, Recurring [Member] | Interest Rate Swaps [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[6],[7]	630	625
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[6],[8]	154	148
Fair Value, Measurements, Recurring [Member] | Foreign Currency Swap [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[6],[7]	92	79
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[6],[8]	710	1,374
Fair Value, Measurements, Recurring [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Assets, Fair Value Disclosure [Abstract]
Derivative financial instruments in a receivable position	[6],[7]	110	551
Selected financial liabilities measured at fair value on a recurring basis
Derivative financial instruments in a liability position	[6],[8]	309	143
Fair Value, Measurements, Recurring [Member] | Available-for-sale Debt Securities [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[4],[6]	16,598	18,632
Fair Value, Measurements, Recurring [Member] | Money Market Funds [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[6]	1,824	1,445
Fair Value, Measurements, Recurring [Member] | Equity Securities [Member]
Assets, Fair Value Disclosure [Abstract]
Available-for-sale securities	[4],[6]	$ 1,032	$ 540
[1]	Amounts may not add due to rounding.
[2]	The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities at cost, and short-term borrowings not measured at fair value on a recurring basis were not significant as of October 1, 2017 or December 31, 2016 . The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs, using a market approach. The fair value measurements of our priv
[3]	The fair value of our long-term debt (not including the current portion of long-term debt) was $39.0 billion as of October 1, 2017 and $34.9 billion as of December 31, 2016 . The fair value measurements for our long-term debt are based on Level 2 inputs, using a market approach. Long-term debt includes foreign currency long-term borrowings with fair values of $4.7 billion as of October 1, 2017
[4]	Gross unrealized gains and losses are not significant, except as of October 1, 2017 , available-for-sale equity securities’ unrealized gains are $406 million and unrealized losses are $119 million
[5]	As of October 1, 2017 , trading funds and securities are composed of $274 million of trading equity funds and $74 million of trading debt funds. As of December 31, 2016 , trading funds and securities are composed of $236 million of trading equity funds and $89 million of trading debt funds. As of October 1, 2017 and December 31, 2016 , trading equity funds of $63 million and $71 million
[6]	We use a market approach in valuing financial instruments on a recurring basis. All of our financial assets and liabilities measured at fair value on a recurring basis use Level 2 inputs in the calculation of fair value, except 5%
[7]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $40 million as of October 1, 2017 ; and foreign currency forward-exchange contracts with fair values of $162 million as of December 31, 2016
[8]	Designated as hedging instruments, except for certain contracts used as offsets; namely, foreign currency forward-exchange contracts with fair values of $60 million as of October 1, 2017 ; and foreign currency swaps with fair values of $269 million and foreign currency forward-exchange contracts with fair values of $113 million as of December 31, 2016

Financial Instruments - Asset52

Financial Instruments - Assets and Liabilities Measured on Recurring Basis - Footnotes (Detail) - USD ($) $ in Millions	9 Months Ended
	Oct. 01, 2017	Dec. 31, 2016
Footnotes to selected financial assets and liabilities:
Gross unrealized gain	$ 406
Gross unrealized loss	$ 119
Fair Value, Measurements, Recurring [Member]
Footnotes to selected financial assets and liabilities:
Percentage of financial assets and liabilities measured at fair value inputs Level 1 and Level 3 inputs (less than)	5.00%
Trading equity funds	$ 274	$ 236
Trading debt funds	74	89
Trading securities held in trust	63	71
Not Designated as Hedging Instrument [Member] | Foreign Currency Forward-Exchange Contracts [Member] | Fair Value, Measurements, Recurring [Member]
Footnotes to selected financial assets and liabilities:
Instruments used as offsets (assets)	40	162
Instruments used as offsets (liabilities)	60	113
Not Designated as Hedging Instrument [Member] | Foreign Currency Swap [Member] | Fair Value, Measurements, Recurring [Member]
Footnotes to selected financial assets and liabilities:
Instruments used as offsets (liabilities)		269
Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Footnotes to selected financial assets and liabilities:
Fair value of long-term debt	39,000	$ 34,900
Foreign Currency Long Term Debt [Member] | Level 2 [Member] | Estimate of Fair Value Measurement [Member]
Footnotes to selected financial assets and liabilities:
Fair value of long-term debt	$ 4,700

Financial Instruments - Balance

Financial Instruments - Balance Sheet Grouping (Detail) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Assets
Selected financial assets		$ 22,815	$ 24,175
Liabilities
Selected financial liabilities		45,124	43,750
Cash and Cash Equivalents [Member]
Assets
Selected financial assets		526	547
Short-term Investments [Member]
Assets
Selected financial assets		14,146	15,255
Other Current Assets [Member]
Assets
Selected financial assets	[1]	288	567
Long-term Investments [Member]
Assets
Selected financial assets		7,311	7,116
Other Noncurrent Assets [Member]
Assets
Selected financial assets	[2]	543	689
Short-Term Borrowings, Including Current Portion of Long-Term Debt [Member]
Liabilities
Selected financial liabilities		9,448	10,688
Other Current Liabilities [Member]
Liabilities
Selected financial liabilities	[3]	277	443
Long-term debt [Member]
Liabilities
Selected financial liabilities		34,503	31,398
Other Noncurrent Liabilities [Member]
Liabilities
Selected financial liabilities	[4]	$ 896	$ 1,222
[1]	As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $97 million ), foreign currency swaps ( $86 million ) and foreign currency forward-exchange contracts ( $105 million ) and, as of December 31, 2016 , include interest rate swaps ( $26 million ), foreign currency swaps ( $43 million ) and foreign currency forward-exchange contracts ( $497 million
[2]	As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $532 million ), foreign currency swaps ( $6 million ) and foreign currency forward-exchange contracts ( $5 million ) and, as of December 31, 2016 , include interest rate swaps ( $599 million ), foreign currency swaps ( $36 million ) and foreign currency forward-exchange contracts ( $54 million
[3]	As of October 1, 2017 , derivative instruments at fair value include foreign currency forward-exchange contracts ( $276 million ) and interest rate swaps ( $1 million ) and, as of December 31, 2016 , include interest rate swaps ( $1 million ), foreign currency swaps ( $300 million ) and foreign currency forward-exchange contracts ( $143 million
[4]	As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $153 million ), foreign currency swaps ( $710 million ) and foreign currency forward-exchange contracts ( $33 million ) and, as of December 31, 2016 , include interest rate swaps ( $147 million ) and foreign currency swaps ( $1.1 billion

Financial Instruments - Balan54

Financial Instruments - Balance Sheet Grouping - Footnotes (Detail) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		$ 22,815	$ 24,175
Selected financial liabilities		45,124	43,750
Other Current Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[1]	288	567
Other Current Assets [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		97	26
Other Current Assets [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		86	43
Other Current Assets [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		105	497
Other Noncurrent Assets [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets	[2]	543	689
Other Noncurrent Assets [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		532	599
Other Noncurrent Assets [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		6	36
Other Noncurrent Assets [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial assets		5	54
Other Current Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[3]	277	443
Other Current Liabilities [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		1	1
Other Current Liabilities [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities			300
Other Current Liabilities [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		276	143
Other Noncurrent Liabilities [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities	[4]	896	1,222
Other Noncurrent Liabilities [Member] | Interest Rate Swaps [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		153	147
Other Noncurrent Liabilities [Member] | Foreign Currency Swap [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		710	$ 1,100
Other Noncurrent Liabilities [Member] | Foreign Currency Forward-Exchange Contracts [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Selected financial liabilities		$ 33
[1]	As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $97 million ), foreign currency swaps ( $86 million ) and foreign currency forward-exchange contracts ( $105 million ) and, as of December 31, 2016 , include interest rate swaps ( $26 million ), foreign currency swaps ( $43 million ) and foreign currency forward-exchange contracts ( $497 million
[2]	As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $532 million ), foreign currency swaps ( $6 million ) and foreign currency forward-exchange contracts ( $5 million ) and, as of December 31, 2016 , include interest rate swaps ( $599 million ), foreign currency swaps ( $36 million ) and foreign currency forward-exchange contracts ( $54 million
[3]	As of October 1, 2017 , derivative instruments at fair value include foreign currency forward-exchange contracts ( $276 million ) and interest rate swaps ( $1 million ) and, as of December 31, 2016 , include interest rate swaps ( $1 million ), foreign currency swaps ( $300 million ) and foreign currency forward-exchange contracts ( $143 million
[4]	As of October 1, 2017 , derivative instruments at fair value include interest rate swaps ( $153 million ), foreign currency swaps ( $710 million ) and foreign currency forward-exchange contracts ( $33 million ) and, as of December 31, 2016 , include interest rate swaps ( $147 million ) and foreign currency swaps ( $1.1 billion

Financial Instruments - Investm

Financial Instruments - Investments in Debt Securities (Detail) $ in Millions	Oct. 01, 2017USD ($)
Total Debt Securities [Line Items]
Debt securities maturities within one year	$ 12,818
Debt securities maturities over 1 to 5 years	3,694
Debt securities maturities over 5 to 10 years	1,532
Debt securities maturities over 10 years	18
Total debt securities	18,061
Corporate debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	2,741	[1]
Available-for-sale debt securities maturities over 1 to 5 years	2,591	[1]
Available-for-sale debt securities maturities over 5 to 10 years	1,525	[1]
Available-for-sale debt securities maturities over 10 years	17	[1]
Available-for-sale debt securities maturities total	6,874	[1]
Western European, Asian and other government debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	6,071	[2]
Available-for-sale debt securities maturities over 1 to 5 years	268	[2]
Available-for-sale debt securities maturities over 5 to 10 years	0	[2]
Available-for-sale debt securities maturities over 10 years	0	[2]
Available-for-sale debt securities maturities total	6,339	[2]
Western European, Scandinavia and other government agency debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	1,955	[2]
Available-for-sale debt securities maturities over 1 to 5 years	42	[2]
Available-for-sale debt securities maturities over 5 to 10 years	0	[2]
Available-for-sale debt securities maturities over 10 years	0	[2]
Available-for-sale debt securities maturities total	1,998	[2]
Supranational debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	387	[2]
Available-for-sale debt securities maturities over 1 to 5 years	195	[2]
Available-for-sale debt securities maturities over 5 to 10 years	0	[2]
Available-for-sale debt securities maturities over 10 years	0	[2]
Available-for-sale debt securities maturities total	582	[2]
Government National Mortgage Association and other U.S. government guaranteed asset-back securities [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	42
Available-for-sale debt securities maturities over 1 to 5 years	424
Available-for-sale debt securities maturities over 5 to 10 years	0
Available-for-sale debt securities maturities over 10 years	0
Available-for-sale debt securities maturities total	466
Other asset-backed debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	161	[3]
Available-for-sale debt securities maturities over 1 to 5 years	61	[3]
Available-for-sale debt securities maturities over 5 to 10 years	3	[3]
Available-for-sale debt securities maturities over 10 years	0	[3]
Available-for-sale debt securities maturities total	226	[3]
U.S. government debt [Member]
Total Debt Securities [Line Items]
Available-for-sale debt securities maturities within 1 year	0
Available-for-sale debt securities maturities over 1 to 5 years	112
Available-for-sale debt securities maturities over 5 to 10 years	0
Available-for-sale debt securities maturities over 10 years	0
Available-for-sale debt securities maturities total	112
Time deposits and other [Member]
Total Debt Securities [Line Items]
Held-to-maturity debt securities maturities within 1 year	1,133
Held-to-maturity debt securities with maturities over 1 to 5 years	0
Held-to-maturity debt securities maturities over 5 to 10 years	3
Held-to-maturity debt securities maturities over 10 years	0
Held-to-maturity debt securities maturities total	1,137
Western European government debt [Member]
Total Debt Securities [Line Items]
Held-to-maturity debt securities maturities within 1 year	326	[2]
Held-to-maturity debt securities with maturities over 1 to 5 years	0	[2]
Held-to-maturity debt securities maturities over 5 to 10 years	0	[2]
Held-to-maturity debt securities maturities over 10 years	0	[2]
Held-to-maturity debt securities maturities total	$ 326	[2]
[1]	Issued by a diverse group of corporations, with a significant concentration in the technology sector, virtually all of which are investment-grade.
[2]	Issued by governments, government agencies or supranational entities, as applicable, all of which are high quality.
[3]	Includes receivable-backed, loan-backed, and mortgage-backed securities, all of which are high quality and in senior positions in the capital structure of the security. Receivable-backed securities are collateralized by credit cards receivables, loan-backed securities are collateralized by senior secured obligations of a diverse pool of companies or student loans, and mortgage-backed securities are collateralized by diversified pools of residential and commercial mortgages.

Financial Instruments - Short-T

Financial Instruments - Short-Term Borrowings (Details) - USD ($) $ in Billions	Oct. 01, 2017	Dec. 31, 2016
Commercial Paper [Member]
Short-term Debt [Line Items]
Commercial paper	$ 6.1	$ 5.8

Financial Instruments - Long-Te

Financial Instruments - Long-Term Debt (Details) € in Millions, $ in Millions		9 Months Ended
		Oct. 01, 2017USD ($)	Oct. 01, 2017EUR (€)	Apr. 02, 2017USD ($)
Debt Instrument [Line Items]
Debt issued		$ 34,503
Senior Notes [Member]
Debt Instrument [Line Items]
Debt issued	[1]	5,797
Debt issued				$ 5,279
Senior Notes [Member] | Three-month EURIBOR Plus 0.20% floating rate notes (2019 Notes) [Member]
Debt Instrument [Line Items]
Debt issued		1,479	€ 1,250
Senior Notes [Member] | 0.00% euro Notes (2020 Notes) [Member]
Debt Instrument [Line Items]
Debt issued	[2]	$ 1,183	€ 1,000
Stated interest rate		0.00%	0.00%
Senior Notes [Member] | 0.25% euro Notes (2022 Notes) [Member]
Debt Instrument [Line Items]
Debt issued	[2]	$ 1,183	€ 1,000
Stated interest rate		0.25%	0.25%
Senior Notes [Member] | 1.00% euro Notes (2027 Notes) [Member]
Debt Instrument [Line Items]
Debt issued	[2]	$ 887	€ 750
Stated interest rate		1.00%	1.00%
Senior Notes [Member] | Euro Long-term Debt [Member]
Debt Instrument [Line Items]
Debt issued	[3]	$ 4,732	€ 4,000
Weighted average effective interest rate		0.23%	0.23%
Senior Notes [Member] | 4.20% Notes (2047 Notes) [Member]
Debt Instrument [Line Items]
Debt issued	[4]	$ 1,065
Stated interest rate		4.20%	4.20%
EURIBOR [Member] | Senior Notes [Member] | Three-month EURIBOR Plus 0.20% floating rate notes (2019 Notes) [Member]
Debt Instrument [Line Items]
Interest rate		0.20%
Floor interest rate		0.00%
Maximum [Member] | German Government Bond Rate [Member] | Senior Notes [Member]
Debt Instrument [Line Items]
Redemption basis spread		0.15%
[1]	The aggregate amount at issuance date was $5,279 million
[2]	Redeemable at any time, in whole, or in part, at our option prior to 30 to 90 days of maturity date at the comparable German government bond rate, plus 0.15%
[3]	The weighted-average effective interest rate for the euro notes at issuance was 0.23%
[4]	The notes, issued in U.S. dollars in Taiwan, are redeemable, at our option, in whole but not in part, on each March 17 on or after March 17, 2020.

Financial Instruments - Long-58

Financial Instruments - Long-Term Debt - Maturities (Details) $ in Millions	Oct. 01, 2017USD ($)
Financial Instruments [Abstract]
2,018	$ 481
2,019	4,825
2,020	1,534
2,021	4,502
After 2,021	23,162
Total	$ 34,503

Financial Instruments - Other N

Financial Instruments - Other Noncurrent Liabilities (Detail) - USD ($) $ in Millions		1 Months Ended
		Aug. 31, 2017	Jun. 30, 2017	Oct. 01, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				$ 37,492	$ 35,664
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net	[1]			35,625	$ 33,740
Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				371
U.S. [Member] | Besponsa [Member]
Finite-Lived Intangible Assets [Line Items]
Term over which fixed annual payments are to be made		9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement		$ 296
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				248
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				233
U.S. [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				15
EU [Member] | Besponsa [Member]
Finite-Lived Intangible Assets [Line Items]
Term over which fixed annual payments are to be made			9 years
Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement			$ 148
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				123
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Noncurrent Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				117
EU [Member] | Besponsa [Member] | Developed Technology Rights [Member] | Other Current Liabilities [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, net				$ 6
[1]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A ) and (v) impairments of Developed technology rights (see Note 4)

Financial Instruments - Derivat

Financial Instruments - Derivative Financial Instruments and Hedging Activities (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt		$ 34,503		$ 34,503
Pre-tax loss on foreign currency forward exchange contracts				97
Pre-tax loss to be reclassified		63		63
Gain (loss) recognized as an offset		(4)		67
Gain (loss) on cash flow hedge ineffectiveness		0	$ 0	0	$ 0
Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(216)	(126)	(666)	(1,014)
Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	34	18	(117)	(56)
Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	(55)	(150)	394	(283)
Other Derivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	1	0	1	1
Other Derivative Instruments [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0	0	0
Other Derivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	0	0	0	0
Interest Rate Contract [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount		12,400		12,400
Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	218	87	455	(204)
Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0	0	0
Foreign Currency Swap [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	148	(39)	419	(165)
Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0	0	0
Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	(4)	(1)	(9)
Foreign Currency Swap [Member] | Not Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	0	0	0	0
Foreign Currency Forward-Exchange Contracts [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Derivative asset, notional amount		31,500		31,500
Notional amount		3,900		3,900
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(269)	(212)	(604)	(770)
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	1	2	(5)	1
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	(204)	(111)	(26)	(118)
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0	0	(15)
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0	0	1
Foreign Currency Forward-Exchange Contracts [Member] | Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	0	0	0	0
Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	0	0	0	0
Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	33	20	(111)	(49)
Foreign Currency Forward-Exchange Contracts [Member] | Not Designated as Hedging Instrument [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	0	0	0	0
Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]			0	(26)
Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]			0	0
Foreign Currency Short Term Borrowings [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]			0	0
Foreign Currency Long Term Debt [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other Comprehensive Income (Loss) [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OCI (Effective Portion)	[1],[2]	(166)	0	(518)	0
Foreign Currency Long Term Debt [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Recognized in OID	[2],[3],[4]	0	0	0	0
Foreign Currency Long Term Debt [Member] | Net Investment Hedging, Nonderivative Instruments [Member] | Reclassification out of Accumulated Other Comprehensive Income [Member] | Other (Income)/Deductions, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Amount of Gains/(Losses) Reclassified from OCI into OID and COS (Effective Portion)	[1],[2]	0	$ 0	0	$ 0
Unsecured Debt [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Long-term debt		$ 2,000		$ 2,000
[1]	For derivative financial instruments in cash flow hedge relationships, the effective portion is included in Other comprehensive income––Unrealized holding losses on derivative financial instruments, net . For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the effective portion is included in Other comprehensive income––Foreign currency translation adjustments, net.
[2]	OID = Other (income)/deductions—net, included in Other (income)/deductions—net in the condensed consolidated statements of income. COS = Cost of sales, included in Cost of sales in the condensed consolidated statements of income. OCI = Other comprehensive income/(loss), included in the condensed consolidated statements of comprehensive income
[3]	Includes gains and losses attributable to derivative instruments designated and qualifying as fair value hedges (primarily interest rate swaps), as well as the offsetting gains and losses attributable to the hedged items in such hedging relationships.
[4]	There was no significant ineffectiveness for any period presented.

Financial Instruments - Narrati

Financial Instruments - Narrative (Detail) $ in Millions	9 Months Ended
	Oct. 01, 2017USD ($)
Concentration Risk [Line Items]
Derivatives in a net liability position	$ 491
Collateral posted	505
Technology sector [Member]
Concentration Risk [Line Items]
Maximum exposure, amount	946
Cash and Cash Equivalents [Member]
Concentration Risk [Line Items]
Cash collateral received	$ 232

Inventories (Detail)

Inventories (Detail) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Inventory Disclosure [Abstract]
Finished goods		$ 2,977	$ 2,293
Work-in-process		4,070	3,696
Raw materials and supplies		879	793
Inventories	[1],[2]	7,925	6,783
Noncurrent inventories not included above	[3]	$ 669	$ 683
[1]	Amounts may not add due to rounding.
[2]	The change from December 31, 2016
[3]	Included in Other noncurrent assets

Identifiable Intangible Asset63

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Detail) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		$ 12,229	$ 16,984
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		93,650	87,351
Finite-lived intangible assets, accumulated amortization	[1]	(56,158)	(51,687)
Finite-lived Intangible Assets, less Accumulated Amortization		37,492	35,664
Intangible assets, gross carrying amount	[1]	105,879	104,335
Finite-lived intangible assets, accumulated amortization	[1]	(56,158)	(51,687)
Identifiable Intangible Assets, less Accumulated Amortization	[1],[2]	49,721	52,648
Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets		6,937	6,883
In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Indefinite-lived intangible assets	[3]	5,292	10,101
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount	[3]	89,585	83,390
Finite-lived intangible assets, accumulated amortization	[3]	(53,960)	(49,650)
Finite-lived Intangible Assets, less Accumulated Amortization	[3]	35,625	33,740
Finite-lived intangible assets, accumulated amortization	[3]	(53,960)	(49,650)
Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		2,135	2,092
Finite-lived intangible assets, accumulated amortization		(1,127)	(1,032)
Finite-lived Intangible Assets, less Accumulated Amortization		1,008	1,060
Finite-lived intangible assets, accumulated amortization		(1,127)	(1,032)
License Agreements and Other [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived intangible assets, gross carrying amount		1,930	1,869
Finite-lived intangible assets, accumulated amortization		(1,071)	(1,005)
Finite-lived Intangible Assets, less Accumulated Amortization		859	864
Finite-lived intangible assets, accumulated amortization		$ (1,071)	$ (1,005)
[1]	The decrease in I dentifiable intangible assets, less accumulated amortization , is primarily due to amortization, measurement period adjustments related to Medivation (see Note 2A ), as well as impairments of Developed technology rights (see Note 4) , partially offset by assets acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ) and the assets recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E
[2]	Amounts may not add due to rounding.
[3]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A ) and (v) impairments of Developed technology rights (see Note 4)

Identifiable Intangible Asset64

Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - USD ($) $ in Millions		Oct. 01, 2017	Dec. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Increase in finite-lived intangible assets		$ 37,492	$ 35,664
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Increase in finite-lived intangible assets	[1]	35,625	$ 33,740
Eucrisa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Transfer of intangible assets during period		4,800
Besponsa [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Increase in finite-lived intangible assets		371
In Process Research and Development [Member] | Eucrisa [Member]
Finite-Lived Intangible Assets [Line Items]
Transfer of intangible assets during period		$ (4,800)
[1]	The changes in the gross carrying amount of Developed technology rights and IPR&D primarily reflect (i) the transfer of $4.8 billion from IPR&D to Developed technology rights to reflect the approval of Eucrisa, (ii) the Developed technology rights and IPR&D acquired as part of the acquisition of AstraZeneca’s small molecule anti-infectives business (see Note 2A ), (iii) the Developed technology rights of $371 million recorded in connection with the EU and U.S. approvals of Besponsa (see Note 7E ), partially offset by (iv) measurement period adjustments related to Medivation (see Note 2A ) and (v) impairments of Developed technology rights (see Note 4)

Identifiable Intangible Asset65

Identifiable Intangible Assets and Goodwill - Finite-lived Intangible Assets Percentage of Total Intangibles (Details)	Oct. 01, 2017
Operating Segments [Member] | Developed Technology Rights [Member] | IH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	68.00%
Operating Segments [Member] | Developed Technology Rights [Member] | EH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	32.00%
Operating Segments [Member] | Brands [Member] | IH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	75.00%
Operating Segments [Member] | Brands [Member] | EH [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	25.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Finite-Lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%

Identifiable Intangible Asset66

Identifiable Intangible Assets and Goodwill - Indefinite-lived Intangible Assets Percentage of Total Intangibles (Details)	Oct. 01, 2017
IH [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	71.00%
IH [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	80.00%
EH [Member] | Operating Segments [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	29.00%
EH [Member] | Operating Segments [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	13.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | Brands [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	0.00%
Pfizer's Worldwide Research and Development [Member] | Segment Reconciling Items [Member] | In Process Research and Development [Member]
Indefinite-lived Intangible Assets [Line Items]
Percentage of total identifiable intangible assets, less accumulated amortization	7.00%

Identifiable Intangible Asset67

Identifiable Intangible Assets and Goodwill - Narrative (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Finite-Lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Amortization expense for finite-lived intangible assets	$ 1,200	$ 988	$ 3,600	$ 3,000

Identifiable Intangible Asset68

Identifiable Intangible Assets and Goodwill - Goodwill (Detail) $ in Millions	9 Months Ended
	Oct. 01, 2017USD ($)
Goodwill [Roll Forward]
Balance, December 31, 2016	$ 54,449	[1]
Additions	664	[2]
Other	966	[3]
Balance, October 1, 2017	56,078	[1]
IH [Member]
Goodwill [Roll Forward]
Balance, December 31, 2016	30,134
Additions	572	[2]
Other	491	[3]
Balance, October 1, 2017	31,197
EH [Member]
Goodwill [Roll Forward]
Balance, December 31, 2016	24,315
Additions	92	[2]
Other	475	[3]
Balance, October 1, 2017	$ 24,882
[1]	Amounts may not add due to rounding.
[2]	IH additions primarily represent measurement period adjustments related to our Medivation acquisition, and EH additions relate to our acquisition of AstraZeneca’s small molecule anti-infectives business, which are subject to change until we complete the valuation of assets acquired and liabilities assumed (see Note 2A
[3]	Primarily reflects the impact of foreign exchange and an adjustment of our estimate of goodwill associated with the HIS net assets sold.

Pension and Postretirement Be69

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 67	$ 69	$ 202	[1]	$ 193	[1]
Interest cost	157	218	478	[1]	486	[1]
Expected return on plan assets	(248)	(239)	(759)	[1]	(721)	[1]
Amortization of:
Actuarial losses	91	99	302	[1]	297	[1]
Prior service costs (credits)	0	1	3	[1]	4	[1]
Curtailments	1	2	10	[1]	5	[1]
Settlements	30	21	54	[1]	52	[1]
Defined benefit plan, net periodic benefit cost	99	170	292	[1]	316	[1]
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	44	41	127		126
Interest cost	52	58	152		178
Expected return on plan assets	(87)	(95)	(256)		(291)
Amortization of:
Actuarial losses	29	23	86		70
Prior service costs (credits)	(1)	(1)	(3)		(2)
Curtailments	(2)	0	(2)		(1)
Settlements	0	1	3		2
Defined benefit plan, net periodic benefit cost	35	27	106		81
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	6	5	18		14
Interest cost	13	18	41		40
Expected return on plan assets	0	0	0		0
Amortization of:
Actuarial losses	12	9	37		27
Prior service costs (credits)	0	0	(1)		(1)
Curtailments	0	1	0		1
Settlements	7	7	32		23
Defined benefit plan, net periodic benefit cost	39	39	127		105
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	10	11	32		31
Interest cost	23	33	68		77
Expected return on plan assets	(9)	(8)	(27)		(25)
Amortization of:
Actuarial losses	8	9	23		23
Prior service costs (credits)	(45)	(45)	(137)		(127)
Curtailments	(3)	(8)	(15)		(14)
Settlements	0	0	0		0
Defined benefit plan, net periodic benefit cost	$ (17)	$ (9)	$ (57)		$ (36)
[1]	In April 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the $156 million net pension benefit obligation and recorded a pretax settlement gain of $41 million , partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately $30 million in Restructuring charges and certain acquisition-related costs during the second quarter of 2017 (see Note 3

Pension and Postretirement Be70

Pension and Postretirement Benefit Plans - Net Periodic Benefit Cost - Footnotes (Details) - Hospira [Member] - Pension Plan [Member] - U.S. [Member] - Qualified [Member] $ in Millions	1 Months Ended
	Apr. 30, 2017USD ($)
Defined Benefit Plan Disclosure [Line Items]
Decrease in pension benefit obligation in connection with Hospira pension plan	$ 156
Pretax settlement gain	41
Actuarial losses and prior service costs recognized upon plan settlement	$ 30

Pension and Postretirement Be71

Pension and Postretirement Benefit Plans (Detail) - USD ($) $ in Millions		1 Months Ended	9 Months Ended
		Jan. 31, 2017	Oct. 01, 2017
Pension Plan [Member] | U.S. [Member] | Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended October 1, 2017		$ 1,000	$ 1,095
Expected contributions from our general assets during 2017	[1]		1,095
Pension Plan [Member] | International [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended October 1, 2017			134
Expected contributions from our general assets during 2017	[1]		170
Supplemental Employee Retirement Plan [Member] | U.S. [Member] | Non-Qualified [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended October 1, 2017			121
Expected contributions from our general assets during 2017	[1]		146
Postretirement Plans [Member]
Defined Benefit Plan Disclosure [Line Items]
Contributions from our general assets for the nine months ended October 1, 2017			158
Expected contributions from our general assets during 2017	[1]		$ 204
[1]	Contributions expected to be made for 2017 are inclusive of amounts contributed during the nine months ended October 1, 2017 , including the $1.0 billion

Earnings Per Common Share Att72

Earnings Per Common Share Attributable to Common Shareholders (Details) - USD ($) shares in Millions, $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
EPS Numerator––Basic
Income from continuing operations	[1],[2],[3]	$ 2,858	$ 1,355	$ 9,064	$ 6,465
Less: Net income attributable to noncontrolling interests		18	0	32	25
Income from continuing operations attributable to Pfizer Inc.	[1]	2,840	1,355	9,032	6,440
Less: Preferred stock dividends––net of tax		0	0	1	1
Income from continuing operations attributable to Pfizer Inc. common shareholders	[1]	2,839	1,355	9,032	6,439
Discontinued operations––net of tax	[3]	0	0	1	0
Net income attributable to Pfizer Inc. common shareholders	[1]	2,839	1,355	9,033	6,439
EPS Numerator––Diluted
Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions	[1]	2,840	1,355	9,032	6,440
Discontinued operations––net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions		0	0	1	0
Net income attributable to Pfizer Inc. common shareholders and assumed conversions	[1]	$ 2,840	$ 1,355	$ 9,034	$ 6,440
EPS Denominator
Weighted-average number of common shares outstanding––Basic	[3]	5,951	6,066	5,972	6,095
Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements (shares)	[1]	89	84	85	80
Weighted-average number of common shares outstanding––Diluted	[1],[2],[3]	6,041	6,150	6,057	6,175
Equity Option [Member]
EPS Denominator
Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans (shares)	[1],[4]	47	38	47	60
[1]	Amounts for the third quarter and first nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016 , as of January 1, 2016, that requires, when applying the treasury stock method for shares that could be repurchased, that the assumed proceeds no longer include the amount of excess tax benefit (see Note 1B
[2]	Amounts for the three and nine months ended October 2, 2016 have been revised from previously reported amounts to reflect the adoption of a new accounting standard in the fourth quarter of 2016, as of January 1, 2016. For additional information, see Note 1B . Basis of Presentation and Significant Accounting Policies––Adoption of New Accounting Standards
[3]	Amounts may not add due to rounding.
[4]	These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.

Commitments and Contingencies (

Commitments and Contingencies (Details) - USD ($) $ / shares in Units, shares in Millions	May 19, 2017	Feb. 06, 2017	Feb. 02, 2017	May 19, 2017	Oct. 01, 2017
Share Repurchase Agreement with Citibank [Member]
Accelerated Share Repurchases [Line Items]
Share repurchase agreement, amount			$ 5,000,000,000
Accelerated share repurchases, cash paid		$ 5,000,000,000
Shares repurchased	24	126
Shares repurchased, price per share (in dollars per share)		$ 31.73
Shares received in initial delivery, percentage of agreement amount			80.00%
Average price paid for shares delivered under agreement (in dollars per share)				$ 33.31
Remaining authorized repurchase amount					$ 6,400,000,000
Pro Forma [Member] | Mylotarg [Member]
Accelerated Share Repurchases [Line Items]
Research arrangement, fixed payment obligation					$ 310,000,000
Term over which additional fixed payments are to be made					10 years

Commitments and Contingencies74

Commitments and Contingencies (Actions In Which We Are The Plaintiff) (Details)

Aug. 10, 2017Patents

Oct. 31, 2017Patents

Sep. 30, 2017Patents

Jul. 31, 2017Patents

Mar. 31, 2017Patents

Feb. 28, 2017Patents

Jan. 31, 2017Patents

Aug. 31, 2016Patents

Jul. 31, 2016Patents

Jan. 31, 2016Patents

Dec. 31, 2015Patents

Jul. 31, 2015Defendant

Jun. 30, 2015Patents

Jan. 31, 2015Patents

Jun. 30, 2013Patents

Jul. 31, 2015Defendant

Apr. 30, 2017PatentsDefendant

Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Fresenius [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

4

Patent Infringement [Member] | Bosulif [Member] | Wyeth Versus Sun [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

5

5

5

Number of patents infringed upon

5

Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Judicial Ruling [Member]

Gain Contingencies [Line Items]

Number of patents not infringed upon

5

Number of patents infringed upon

5

5

5

Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of defendants | Defendant

4

Patent Infringement [Member] | Toviaz [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Settled Litigation [Member]

Gain Contingencies [Line Items]

Number of defendants | Defendant

4

Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Mylan Laboratories Limited [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

3

3

Patent Infringement [Member] | Toviaz Composition-of-matter Patents [Member] | Pfizer Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus MicroLabs [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Zydus [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Prinston and Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

2

Patent Infringement [Member] | Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

3

Number of defendants | Defendant

25

Patent Infringement [Member] | Bavencio [Member] | Pfizer Versus BMS, E.R. Squibb & Sons, Ono Pharmaceutical and Tasuku Honjo [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents

1

Subsequent Event [Member] | Patent Infringement [Member] | Xeljanz [Member] | Pfizer Versus Breckenridge [Member] | Pending Litigation [Member]

Gain Contingencies [Line Items]

Number of patents allegedly infringed upon

4

Number of patents due to expire in December 2020

3

Number or patents due to expire in December 2025

1

Commitments and Contingencies75

Commitments and Contingencies (Actions In Which We Are The Defendant) (Detail) £ in Millions, $ in Millions	1 Months Ended
	Oct. 31, 2017USD ($)	Apr. 30, 2017	Mar. 31, 2015Patents	Mar. 31, 2013lagoon	Oct. 01, 2017Claim	Dec. 31, 2016GBP (£)
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]
Loss Contingencies [Line Items]
Number of patents			6
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Claims dismissed			4
Inflectra [Member] | Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of patents			2
Xtandi [Member] | Regents Versus Medivation [Member] | Settled Litigation [Member]
Loss Contingencies [Line Items]
Percentage of payments Medivation received sought by Regents		10.00%
Damages from Product Defects [Member] | Class Action Versus American Optical Corporation And Various Other Defendants [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim					56,500
Average Wholesale Price [Member] | State of Illinois Versus Pfizer [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Number of pending claims | Claim					1
Environmental Remediation Litigation [Member]
Loss Contingencies [Line Items]
Number of lagoons | lagoon				2
Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]
Loss Contingencies [Line Items]
Imposed fine | £						£ 84.2
Subsequent Event [Member] | Celebrex [Member] | Pending Litigation [Member]
Loss Contingencies [Line Items]
Amount awarded to other party | $	$ 94

Segment, Geographic and Other76

Segment, Geographic and Other Revenue Information - Narrative (Detail) $ in Millions		9 Months Ended
		Oct. 01, 2017USD ($)Operating_Segment	Dec. 31, 2016USD ($)
Segment Reporting [Abstract]
Number of business segments | Operating_Segment		2
Assets | $	[1]	$ 172,151	$ 171,615
[1]	Amounts may not add due to rounding.

Segment, Geographic and Other77

Segment, Geographic and Other Revenue Information (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Segment Reporting Information [Line Items]
Revenues	[1]	$ 13,168	$ 13,045	$ 38,843	$ 39,196
Earnings	[1],[2]	3,585	1,604	11,351	7,575
Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		13,168	13,045	38,843	39,196
Earnings	[2]	7,640	7,315	22,748	22,454
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3],[4]	(759)	(753)	(2,205)	(2,096)
Segment Reconciling Items [Member] | Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	(1,154)	(966)	(3,527)	(3,103)
Segment Reconciling Items [Member] | Acquisition-Related Costs [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	(155)	(280)	(347)	(598)
Segment Reconciling Items [Member] | Certain Significant Items [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[5]	(449)	(1,969)	(797)	(4,112)
Segment Reconciling Items [Member] | Other Unallocated [Member]
Segment Reporting Information [Line Items]
Earnings	[2]	(156)	(206)	(573)	(753)
Corporate [Member]
Segment Reporting Information [Line Items]
Earnings	[2],[3]	(1,382)	(1,537)	(3,948)	(4,217)
IH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		8,118	7,332	23,204	21,471
Earnings	[2]	4,875	4,187	14,190	12,470
EH [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Revenues		5,050	5,712	15,639	17,725
Earnings	[2]	$ 2,765	$ 3,128	$ 8,558	$ 9,985
[1]	Amounts may not add due to rounding.
[2]	Income from continuing operations before provision for taxes on income. IH’s earnings in the third quarter and first nine months of 2017 include d ividend income of $54 million and $211 million , respectively, from our investment in ViiV. For additional information, see
[3]	For a description, see the “Other Costs and Business Activities” section above.
[4]	Other business activities includes the costs managed by our WRD and GPD organizations. Effective in the first quarter of 2017 , Medical, previously reported as part of Other Business Activities, was reclassified to Corporate. We have reclassified approximately $33 million and $94 million of costs from Other Business Activities to Corporate in the third quarter and first nine months of 2016
[5]	Certain significant items are substantive and/or unusual, and in some cases recurring, items (such as restructuring or legal charges) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Earnings in the third quarter of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $90 million , (ii) charges for certain legal matters of $183 million , (iii) income of $12 million , representing an adjustment to amounts previously recorded to write down the HIS net assets to fair value less costs to sell, (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $16 million and (vi) other charges of $45 million . For additional information, see Note 2B, Note 3 and Note 4. For Earnings in the third quarter of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $375 million , (ii) income for certain legal matters of $40 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $126 million , (v) charges for business and legal entity alignment of $69 million and (vi) other charges of $17 million . For additional information, see Note 3 and Note 4 . For Earnings in the first nine months of 2017 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $253 million , (ii) charges for certain legal matters of $191 million , (iii) incremental charges to amounts previously recorded to write down the HIS net assets to fair value less costs to sell of $52 million , (iv) certain asset impairment charges of $127 million , (v) charges for business and legal entity alignment of $54 million and (vi) other charges of $119 million . For additional information, see Note 2B , Note 3 and Note 4 . For Earnings in the first nine months of 2016 , certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $743 million , (ii) charges for certain legal matters of $506 million , (iii) an impairment charge related to the write-down of the HIS net assets to fair value less estimated costs to sell of $1.4 billion , (iv) certain asset impairment charges of $1.1 billion , (v) charges for business and legal entity alignment of $180 million and (vi) other charges of $189 million . For additional information, see Note 3 and Note 4

Segment, Geographic and Other78

Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017		Oct. 02, 2016
Segment Reporting Information [Line Items]
Gain (loss) on sale of HIS net assets	[1]	$ 12	$ (1,422)	$ (52)	[2]	$ (1,422)	[2]
Business and legal entity alignment costs	[3]	16	69	54		180
Income (charges) for certain legal matters	[4]	(183)	40	(194)		(494)
Certain asset impairments	[5]	130	133	143		1,080
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Cost reduction and productivity initiatives excluding acquisition related costs		90	375	253		743
Business and legal entity alignment costs		16	69	54		180
Other charges		45	17	119		189
Income (charges) for certain legal matters		(183)	40	(191)		(506)
Certain asset impairments		127	126	127		1,100
Adjustment [Member] | Corporate [Member]
Segment Reporting Information [Line Items]
Costs and expenses			33			94
HIS [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Gain (loss) on sale of HIS net assets		12	(1,400)	(52)		(1,400)
ViiV Healthcare Limited [Member] | Innovative Health Segment [Member] | Operating Segments [Member]
Segment Reporting Information [Line Items]
Dividend income		$ 54		$ 211
Pfizer's Worldwide Research and Development and Pfizer's Global Product Development [Member] | Adjustment [Member] | Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Costs and expenses			$ (33)			$ (94)
[1]	In the third quarter and first nine months of 2017 , represents adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical. In the third quarter and first nine months of 2016 , represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell.
[2]	Amounts may not add due to rounding.
[3]	In the third quarter and first nine months of 2017 and 2016
[4]	In the third quarter and first nine months of 2017 , primarily includes a $94 million charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which is subject to the negotiation of a final settlement agreement and court approval, and a $79 million charge to reflect damages awarded by a jury in a patent matter. In the first nine months of 2016 , primarily includes amounts to resolve a Multi-District Litigation relating to Celebrex and Bextra that was pending against the Company in New York federal court for $486 million , partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In addition, the first nine months of 2016
[5]	In the third quarter and first nine months of 2017 , primarily includes an intangible asset impairment charge of $127 million related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions. The intangible asset impairment charge for the third quarter and first nine months of 2017 is associated with EH and reflects, among other things, updated commercial forecasts and an increased competitive environment. In the third quarter of 2016 , primarily includes intangible asset impairment charges of $126 million , reflecting $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma and $29 million of other IPR&D assets acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the third quarter of 2016 are associated with the following: EH ( $97 million ) and IH ( $29 million ). In the first nine months of 2016 , primarily includes intangible asset impairment charges of $767 million , reflecting (i) $331 million related to developed technology rights for a generic injectable antibiotic product for the treatment of bacterial infections; and (ii) $265 million related to an IPR&D compound for the treatment of anemia, both acquired in connection with our acquisition of Hospira; (iii) $97 million of sterile injectable IPR&D compounds acquired in connection with our acquisition of InnoPharma; and (iv) $74 million of other IPR&D assets, $45 million of which were acquired in connection with our acquisition of Hospira and $29 million of which were acquired in connection with our acquisition of King in 2011. The intangible asset impairment charges for the first nine months of 2016 are associated with the following: EH ( $738 million ) and IH ( $29 million ). In addition, the first nine months of 2016 includes an impairment loss of $211 million related to Pfizer’s 49% -owned equity-method investment with Hisun in China, Hisun Pfizer, and an impairment loss of $50 million related to Pfizer’s 40% -owned equity-method investment in Teuto. For additional information concerning Hisun Pfizer and Teuto, see Note 2D.

Segment, Geographic and Other79

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 13,168	$ 13,045	$ 38,843	$ 39,196
Percentage Change In Revenue		1.00%		(1.00%)
U.S. [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 6,534	6,530	$ 19,516	19,561
Percentage Change In Revenue		0.00%		0.00%
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	$ 2,163	2,218	$ 6,309	6,982
Percentage Change In Revenue	[2]	(2.00%)		(10.00%)
Developed Rest Of World [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[3]	$ 1,632	1,711	$ 4,797	4,940
Percentage Change In Revenue	[3]	(5.00%)		(3.00%)
Emerging Markets [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[4]	$ 2,839	$ 2,586	$ 8,222	$ 7,714
Percentage Change In Revenue	[4]	10.00%		7.00%
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the third quarter of 2017 and 2016 , and $5.0 billion and $5.3 billion in the first nine months of 2017 and 2016
[3]	Developed Rest of World region includes the following markets: Japan, Canada, Australia, South Korea and New Zealand.
[4]	Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Africa, Eastern Europe, Central Europe, the Middle East and Turkey.

Segment, Geographic and Other80

Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[1]	$ 13,168	$ 13,045	$ 38,843	$ 39,196
Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues	[2]	2,163	2,218	6,309	6,982
Euro Member Countries, Euro [Member] | Developed Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenues		$ 1,700	$ 1,700	$ 5,000	$ 5,300
[1]	Amounts may not add due to rounding.
[2]	Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland. Revenues denominated in euros were $1.7 billion in both the third quarter of 2017 and 2016 , and $5.0 billion and $5.3 billion in the first nine months of 2017 and 2016

Segment, Geographic and Other81

Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Oct. 01, 2017	Oct. 02, 2016	Oct. 01, 2017	Oct. 02, 2016
Revenue from External Customer [Line Items]
Revenues	[1]	$ 13,168	$ 13,045	$ 38,843	$ 39,196
Innovative Health and Essential Health [Member]
Revenue from External Customer [Line Items]
Revenues		13,168	13,045	38,843	39,196
Innovative Health and Essential Health [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,285	1,240	3,810	3,730
Innovative Health and Essential Health [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	308	387	996	1,183
Innovative Health and Essential Health [Member] | Alliance revenues [Member]
Revenue from External Customer [Line Items]
Revenues		741	419	2,112	1,155
Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues	[4]	8,118	7,332	23,204	21,471
Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[5]	5,050	5,712	15,639	17,725
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[6]	2,681	2,708	7,995	8,373
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Lipitor [Member]
Revenue from External Customer [Line Items]
Revenues		491	422	1,341	1,294
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Premarin family [Member]
Revenue from External Customer [Line Items]
Revenues		238	244	711	751
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Norvasc [Member]
Revenue from External Customer [Line Items]
Revenues		226	238	684	714
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | EpiPen [Member]
Revenue from External Customer [Line Items]
Revenues		82	110	253	300
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xalatan/Xalacom [Member]
Revenue from External Customer [Line Items]
Revenues		83	91	241	273
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Effexor [Member]
Revenue from External Customer [Line Items]
Revenues		76	70	215	207
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zoloft [Member]
Revenue from External Customer [Line Items]
Revenues		78	72	215	228
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Zithromax [Member]
Revenue from External Customer [Line Items]
Revenues		61	56	202	203
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Relpax [Member]
Revenue from External Customer [Line Items]
Revenues		50	83	193	248
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Xanax [Member]
Revenue from External Customer [Line Items]
Revenues		58	55	164	163
Legacy Established Products (LEP) [Member] | Essential Health Business [Member] | EH [Member] | Other Legacy Established Products [Member]
Revenue from External Customer [Line Items]
Revenues		1,237	1,268	3,776	3,992
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[7]	1,273	1,461	4,270	4,481
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Medrol [Member]
Revenue from External Customer [Line Items]
Revenues		109	102	352	330
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Sulperazon [Member]
Revenue from External Customer [Line Items]
Revenues		114	102	345	304
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Fragmin [Member]
Revenue from External Customer [Line Items]
Revenues		79	80	221	240
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Tygacil [Member]
Revenue from External Customer [Line Items]
Revenues		60	69	192	203
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | Precedex [Member]
Revenue from External Customer [Line Items]
Revenues		51	64	182	199
Sterile Injectable Pharmaceuticals [Member] | Essential Health Business [Member] | EH [Member] | All Other Sterile Injectable Pharmaceuticals [Member]
Revenue from External Customer [Line Items]
Revenues		860	1,044	2,977	3,206
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[8]	794	1,023	2,398	3,224
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	134	191	428	623
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	102	89	285	286
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Celebrex [Member]
Revenue from External Customer [Line Items]
Revenues		212	194	564	550
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Vfend [Member]
Revenue from External Customer [Line Items]
Revenues		97	140	305	459
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Pristiq [Member]
Revenue from External Customer [Line Items]
Revenues		69	174	230	546
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Zyvox [Member]
Revenue from External Customer [Line Items]
Revenues		68	94	220	334
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | Revatio [Member]
Revenue from External Customer [Line Items]
Revenues		58	73	189	213
Peri-LOE Products [Member] | Essential Health Business [Member] | EH [Member] | All Other Peri-LOE Products [Member]
Revenue from External Customer [Line Items]
Revenues		55	68	176	214
Biosimilars [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[9]	141	83	367	228
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | Inflectra/Remsima [Member]
Revenue from External Customer [Line Items]
Revenues		112	49	284	130
Biosimilars [Member] | Essential Health Business [Member] | EH [Member] | All Other Biosimilars [Member]
Revenue from External Customer [Line Items]
Revenues		28	34	82	97
CentreOne [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[10]	161	156	514	540
Hospira Infusion Systems (HIS) [Member] | Essential Health Business [Member] | EH [Member]
Revenue from External Customer [Line Items]
Revenues	[11]	0	281	97	879
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		2,455	2,243	7,245	6,557
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Lyrica [Member]
Revenue from External Customer [Line Items]
Revenues	[2]	1,150	1,049	3,382	3,107
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Eliquis [Member]
Revenue from External Customer [Line Items]
Revenues		644	449	1,813	1,225
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Chantix / Champix [Member]
Revenue from External Customer [Line Items]
Revenues		240	198	727	631
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Viagra [Member]
Revenue from External Customer [Line Items]
Revenues	[3]	206	297	711	897
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | B M P 2 [Member]
Revenue from External Customer [Line Items]
Revenues		79	63	198	175
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | Toviaz [Member]
Revenue from External Customer [Line Items]
Revenues		62	60	187	191
Internal Medicine [Member] | Innovative Health Business [Member] | IH [Member] | All Other Internal Medicine [Member]
Revenue from External Customer [Line Items]
Revenues		75	128	228	330
Vaccines [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,649	1,641	4,385	4,576
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | Prevnar 13/Prevenar 13 [Member]
Revenue from External Customer [Line Items]
Revenues		1,522	1,536	4,069	4,302
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | FSME-IMMUN/TicoVac [Member]
Revenue from External Customer [Line Items]
Revenues		43	33	119	102
Vaccines [Member] | Innovative Health Business [Member] | IH [Member] | All other Vaccines [Member]
Revenue from External Customer [Line Items]
Revenues		85	72	197	172
Oncology [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,616	1,104	4,551	3,206
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Ibrance [Member]
Revenue from External Customer [Line Items]
Revenues		878	550	2,410	1,492
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Sutent [Member]
Revenue from External Customer [Line Items]
Revenues		276	260	805	823
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xalkori [Member]
Revenue from External Customer [Line Items]
Revenues		146	140	442	415
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Xtandi Alliance [Member]
Revenue from External Customer [Line Items]
Revenues		150	2	422	2
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Inlyta [Member]
Revenue from External Customer [Line Items]
Revenues		84	95	256	304
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | Bosulif [Member]
Revenue from External Customer [Line Items]
Revenues		57	43	163	121
Oncology [Member] | Innovative Health Business [Member] | IH [Member] | All other Oncology [Member]
Revenue from External Customer [Line Items]
Revenues		26	15	54	49
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		1,000	960	2,863	2,907
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Enbrel (Outside the U.S. and Canada) [Member]
Revenue from External Customer [Line Items]
Revenues		613	701	1,818	2,201
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Xeljanz [Member]
Revenue from External Customer [Line Items]
Revenues		348	235	935	649
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | Eucrisa [Member]
Revenue from External Customer [Line Items]
Revenues		15	0	33	0
Inflammation and Immunology (I&I) [Member] | Innovative Health Business [Member] | IH [Member] | All Other Inflammation and Immunology Products [Member]
Revenue from External Customer [Line Items]
Revenues		23	24	78	57
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		569	585	1,637	1,768
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | BeneFIX [Member]
Revenue from External Customer [Line Items]
Revenues		151	176	453	543
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | ReFacto AF/ Xyntha [Member]
Revenue from External Customer [Line Items]
Revenues		140	140	409	408
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Genotropin [Member]
Revenue from External Customer [Line Items]
Revenues		136	147	375	425
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | Somavert [Member]
Revenue from External Customer [Line Items]
Revenues		65	59	182	173
Rare Disease [Member] | Innovative Health Business [Member] | IH [Member] | All Other Rare Disease [Member]
Revenue from External Customer [Line Items]
Revenues		77	64	218	219
Consumer Healthcare [Member] | Innovative Health Business [Member] | IH [Member]
Revenue from External Customer [Line Items]
Revenues		$ 829	$ 798	$ 2,522	$ 2,457
[1]	Amounts may not add due to rounding.
[2]	Lyrica revenues from all of Europe, Russia, Turkey, Israel and Central Asia countries are included in Lyrica EH. All other Lyrica revenues are included in Lyrica IH. Total Lyrica revenues represent the aggregate of worldwide revenues from Lyrica IH and Lyrica EH.
[3]	Viagra revenues from the U.S. and Canada are included in Viagra IH. All other Viagra revenues are included in Viagra EH. Total Viagra revenues represent the aggregate of worldwide revenues from Viagra IH and Viagra EH.
[4]	The IH business encompasses Internal Medicine, Vaccines, Oncology, Inflammation & Immunology, Rare Disease and Consumer Healthcare. Through December 31, 2016, includes Duavive/Duavee and Viviant (recorded in All other Internal Medicine in 2016), which were transferred from Innovative Health to Essential Health effective January 1, 2017 (recorded in All other LEP (EH) beginning January 1, 2017), in order to align these products with our management of the women’s health portfolio within EH.
[5]	The EH business encompasses Legacy Established Products, Sterile Injectable Pharmaceuticals, Peri-LOE Products, Biosimilars, Pfizer CentreOne and HIS (through February 2, 2017) and includes all legacy Hospira commercial operations.
[6]	Legacy Established Products primarily include products that have lost patent protection (excluding Sterile Injectable Pharmaceuticals and Peri-LOE Products). Effective January 1, 2017, All other LEP includes Duavive/Duavee and Viviant, which were transferred from Innovative Health (recorded in All other Internal Medicine (IH) in 2016), in order to align these products with our management of the women’s health portfolio within EH.
[7]	Sterile Injectable Pharmaceuticals include generic injectables and proprietary specialty injectables (excluding Peri-LOE Products).
[8]	Peri-LOE Products include products that have recently lost or are anticipated to soon lose patent protection. These products include: Lyrica in Europe, Russia, Turkey, Israel and Central Asia; Viagra in all countries (excluding the U.S. and Canada); and worldwide revenues for Celebrex, Pristiq, Zyvox, Vfend, Revatio and Inspra.
[9]	Biosimilars include Inflectra/Remsima (biosimilar infliximab) in the U.S. and certain international markets, Nivestim (biosimilar filgrastim) in certain European, Asian and Africa/Middle Eastern markets and Retacrit (biosimilar epoetin zeta) in certain European and Africa/Middle Eastern markets.
[10]	Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis.
[11]	HIS (through February 2, 2017) includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets.